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Human Immunodeficiency Virus type 1 (HIV-1) assembly is a multistep process 
mediated by the viral precursor polyprotein Gag (Pr55
Gag
). Matrix (MA), which 
constitutes the N-terminal domain of Pr55
Gag
, is essential for membrane binding and 
targeting of Gag to the plasma membrane (PM).  MA has a bipartite signal for membrane 
binding: a myristate moiety at the N-terminus and amino acid residues 17-31 that form a 
highly basic region (HBR) on the surface of MA. The N-terminal myristate is normally 
sequestered into the MA globular domain, and a structural change exposes myristate, 
thereby enhancing membrane binding. The HBR on the other hand is thought to bind 
acidic lipids. Previous results from the lab suggest that a PM-specific acidic lipid, 
phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2], is important for Gag localization to 
the PM. 
In this thesis, I have shown that Gag interacts specifically with PI(4,5)P2 and that 
this interaction is important for efficient membrane binding of Gag. To elucidate the 
molecular mechanisms by which Gag-PI(4,5)P2 interaction is regulated, site-directed 
mutagenesis was performed on the MA HBR. Using this approach, we identified three 
lysines that facilitate membrane binding by interacting with PI(4,5)P2. Strikingly, 
mutations in two other lysines in the MA HBR enhance PI(4,5)P2-independent membrane 
binding by exposing myristate. Thus, MA HBR has opposing roles in membrane binding. 
Notably, another major finding of this thesis is that RNA also negatively regulates 
membrane binding of Gag. In the absence but not in the presence of PI(4,5)P2, RNA
bound to the MA HBR abolishes membrane binding of Gag. Overall, the results from this 
thesis suggest that the MA HBR regulates membrane binding both positively by binding 
to PI(4,5)P2 and negatively through myristate sequestration and RNA binding. This 
regulation ensures that Gag is targeted specifically to the PM, where it likely interacts 





Human Immunodeficiency Virus (HIV) is the causative agent of Acquired 
Immune Deficiency Syndrome (AIDS). There are currently 33.3 million people living 
with HIV around the world. Even though researchers have focused on understanding 
various aspects of HIV since its discovery 29 years ago, there is still no vaccine available 
to prevent the spread of infection. The existing anti-retroviral regimen is effective in 
slowing the progression of the disease but the adverse effects and the emergence of drug-
resistant strains still pose a problem. In addition, the current drugs are expensive and are 
not readily accessible to people in developing countries. In 2009 alone, there were 2.6 
million new infections and 1.8 million deaths due to AIDS [1]. Thus, there is a 
continuous need for newer and inexpensive drugs while the quest for an effective vaccine 
continues.  
HIV types, groups and subtypes 
There are two types of HIV: HIV-1 and HIV-2.  HIV-2 is relatively uncommon 
and less efficient at transmission and disease progression. HIV-1 is the major type that is 
responsible for the worldwide pandemic and can be divided into three groups: M (major), 
O (Outlier), N (non-M/O) [2]. In 2009, another new group P was proposed that seem to 
be derived from gorillas and is distinct from the three groups mentioned above [3, 4]. 
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Within group M, there are nine distinct subtypes (A, B, C, D, F, G, H, J, K) and 
several major circulating recombinant forms (CRFs). Half of the global infections are 
caused by subtype C. The second most common is subtype A. Subtype B dominates the 
western world and is the most studied subtype in the research labs. However, it accounts 
for only 12% of global infections. This prevalence should be considered while 
developing drugs as most drugs are tested for efficacy against HIV-1 subtype B and may 
or may not work the same for other subtypes or groups. 
HIV Genome  
HIV is an enveloped virus and belongs to the family Retroviridae. The genome is 
single- stranded RNA about 9 kb in length and encodes three major polyproteins, Gag, 
Pol and Env. In addition, HIV has six accessory proteins: Tat, Rev, Nef, Vpr, Vif and 
Vpu (Fig.1.1). Gag and Pol are made from unspliced RNA, singly spliced RNAs ~4kb 
encode Env, Vpu (Vpx in the case of HIV-2), Vif and Vpr and doubly spliced RNAs 
~2kb encode Tat, Rev and Nef [5]. Gag is the major structural polyprotein that is 
sufficient to form virus-like particle. Pol is made as a fusion with Gag protein through 
ribosomal frameshift and is proteolytically cleaved to form viral enzymes: protease, 
reverse transcriptase and integrase. Env (gp160) is the viral glycoprotein that is cleaved 
to form a surface subunit (gp120) and a transmembrane subunit (gp41). These subunits 
form trimers of heterodimers and decorate the viral lipid bilayer [6, 7]. Tat binds nascent 
viral RNA and transactivates HIV promoter by enhancing transcription initiation and 
stabilizing elongation of full-length viral transcripts [8]. Rev interacts with nuclear export 
machinery to allow unspliced and singly spliced RNA to be transported to the cytosol 
where they can be translated [9]. Unspliced RNA is also packaged as genomic RNA. Nef 
 3 
has several functions, including downregulation of CD4 and MHC-1 molecules from the 
surface of infected cells[10-12]. Vpr is important for the transport of preintegration 
complex to the nucleus and also participates in cell-cycle arrest [13, 14]. Vif reduces 
hypermutation of viral genome by preventing the incorporation of Apolipoprotein B 
mRNA editing enzyme catalytic polypeptide-like 3G (APOBEC3G), a cytidine 
deaminase, into the virions [15]. Vpu degrades CD4 molecules [16]and in addition has 
been recently shown to counteract the cellular restriction factor tetherin [17, 18](For 
review on accessory genes, see [19]). The viral genome itself is structured at several 
levels. It has Trans-Activating Response (TAR) hairpin that interacts with Tat. Primer 
binding site interacts with tRNA
Lys
 that primes reverse transcription. The packaging 
signal ( ) (and kissing loop region within ) interacts with nucleocapsid (NC) domain of 
Gag and is crucial for specific encapsidation of two genomic RNAs into the virion. The 
Rev-response element interacts with Rev allowing export of unspliced or singly spliced 
RNA into the cytosol. In addition, the viral RNA has one major splice donor, several 
splice acceptors and a ribosomal frameshift sequence that allows accurate translation of 
viral proteins. The whole genome structure has been recently analyzed and several 
additional unrecognized regulatory structures were also found [20]. 
HIV life cycle 
HIV life cycle is depicted in Fig. 1.2. 
Attachment and entry 
HIV begins its life cycle by attaching to the cellular receptor CD4 via gp120 [21]. 
This causes structural change within gp120 that facilitates its interaction with one of the 
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coreceptors, CCR5 or CXCR4, depending on the tropism determined by the V3 loop of 
gp120 [22, 23].  Once attached, the structural change in the transmembrane domain, 
gp41, allows the insertion of the fusion peptide in the target cell membrane [6]. This 
leads to the formation of a six-helix bundle that mediates fusion of the viral membrane 
with the cellular membrane [24, 25]. This process is receptor mediated and occurs on the 
plasma membrane of the cell. Recently, however, endocytosis has also been shown as a 
viable pathway for the entry of the virus and both endocytosis of the virus and fusion of 
viral and endocytic membranes seem to be dependent on the cellular protein dynamin 
[26]. Currently, there are two drugs that block entry process by either preventing the 
formation of the six-helix bundle or by blocking CCR5 interaction with gp120 [27].  
Uncoating, reverse transcription and integration 
Once the viral membrane fuses with the cellular membrane either at the plasma 
membrane or endosomes, the viral core is released into the cytosol. The transport of the 
genome towards the nucleus is dependent on microtubules [28]. How and when 
uncoating of the core occurs is still unclear. Integrity and timely disassembly of the 
capsid (CA) protein, a cleavage product of Gag, is required for efficient transport, reverse 
transcription and nuclear import[29], for review see [30]. Species-specific cellular 
restriction factor, Tripartite motif-containing protein 5-  (TRIM5- ) interferes with the 
uncoating process preventing successful reverse transcription and nuclear transport [31]. 
Reverse transcription, where the single stranded RNA is converted to double-stranded 
DNA by the reverse transcriptase is completed during the uncoating process. It is during 
this time, HIV is vulnerable to another cellular restriction factor APOBEC3G, which can 
be incorporated into the virion. APOBEC3G is a cytidine deaminase and causes lethal 
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hypermutation of the viral genome [32, 33]. Viral protein Vif interacts with APOBEC3G 
and facilitates its degradation, thus preventing it from being incorporated into the virion 
[15, 34], for review see [35]. The complex that contains reverse-transcribed DNA and 
several viral and host proteins that allow it to be actively transported into the nucleus is 
called pre-integration complex (PIC). Active transport of PIC is important for infection of 
terminally differentiated cells like macrophages by HIV. Even though viral proteins like 
Vpr, matrix (MA) and integrase have been suggested to mediate entry of PIC into the 
nucleus, their involvement is still controversial [36-38] [39]. tRNAs have also been 
implicated in nuclear import of PIC [40]. Once inside the nucleus, the viral DNA 
integrates into the cellular DNA with the help of integrase. Association of cellular lens 
epithelium derived growth factor (LEDGF) with integrase and chromosomal DNA may 
allow specific targeting of integration near active genes [41] [42]. Rev, on the other hand, 
has been recently shown to interact with LEDGF and limit integration events [43]. There 
are currently several drugs that inhibit reverse transcriptase and a single drug that inhibits 
integrase. Detailed understanding of uncoating and nuclear import is necessary for the 
development of newer drugs that can block HIV replication prior to the integration of the 
viral genome into chromosomal DNA. 
Transcription, RNA export and translation 
Once integrated, the viral DNA is called a provirus. HIV promoter is in the 5’ 
long terminal repeat (LTR) sequence and has regulatory elements, including sites for NF-
B, TATA-box binding protein. The transcription mediated by the cellular RNA 
polymerase II and viral protein Tat is important for both enhancing the rate of 
transcription initiation and for efficient elongation[44], for review see [45]. In addition to 
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interacting with several cellular cofactors involved in initiation and elongation of 
transcription, Tat also recruits chromatin-remodeling proteins to the 5’LTR before the 
assembly of RNA Pol II complex [46] [19]. When viral mRNAs are first produced, most 
viral RNAs that reach the cytoplasm are completely spliced and encode Tat, Rev and Nef. 
Once Rev is made in sufficient amounts, unspliced and singly spliced RNAs are 
transported to the cytoplasm, where they encode the remaining viral proteins. Rev 
interacts with the viral RNA at the RRE and recruits CRM/exportin 1[47]. In addition, it 
interacts with several other nuclear export proteins for the transport of viral RNA to the 
cytosol. Oligomerization of Rev on RRE is important for its function as it may increase 
the concentration of nuclear export signal (NES) sites of Rev on a single mRNA and 
promote efficient export [19, 48]. There are currently no drugs that inhibit either 
transcription or nuclear export of the viral RNAs. 
Assembly and Release 
Once viral structural protein is synthesized as the precursor polyprotein Pr55
Gag
, it 
mediates the virus assembly process.  As defined by sites of the viral protease-dependent 
cleavage that occurs during or after virus release, this polyprotein has four major 
structural domains: MA, CA, NC and p6 [49, 50]. In addition, it also contains spacer 
peptides 1 and 2 (SP1 and 2). Each of these structural domains performs a crucial role 
during the assembly process (Fig. 1.3). MA mediates the targeting of Gag to the site of 
assembly and facilitates membrane binding. The C-terminal domain of CA forms the Gag 
dimerization interface, whereas NC promotes higher order multimerization of Gag 
through binding to RNA, which is thought to serve as a scaffold. In addition, NC contains 
two zinc finger/knuckle structures that are required for specific encapsidation of viral 
 7 
genomic RNA. The late domain motifs in p6 recruit cellular protein complexes called 
endosomal-sorting complex required for transport (ESCRT) that aid in the release of the 
virus from the cell membrane. Approximately 2000 Gag molecules are present within the 
virion and Gag alone is sufficient to form virus-like particles. However, for the virus to 
be infectious, several components need to be at the assembly site for their packaging into 
the virion, including Gag, GagPol, which contains all the viral enzymes, Env, viral RNA, 
and host factors that are required for virus infectivity, such as tRNA
Lys3
 and cyclophilin. 
Once the virus assembles and is ready for release, it encounters another cellular 
restriction factor, tetherin, that acts as a physical leash between viral membrane and cell 
membrane. This leash-like structure keeps the virus tethered to the cell surface. However, 
viral protein Vpu counteracts tetherin by removing it from the assembly site and by 
facilitating its degradation. This counteraction by viral protein is important for efficient 
release of the virus into the extracellular space [17, 18]. Once the virus is released, viral 
protease cleaves the polyprotein Gag and Gag-Pol causing a huge conformational change 
within the virus. This structural change makes the virus infectious and the virus is now 
ready to infect another cell. There are several drugs that inhibit the protease activity. 
However, there are currently no drugs that inhibit the assembly process.  
Gag-RNA interaction is important for assembly and specific RNA encapsidation 
Viral genomic RNA and tRNA
Lys
 that acts as the primer for HIV reverse 
transcription
 
are specifically packaged into the virus particle. In addition, there are 
various cellular RNAs that are either specifically enriched in virus particles like 7SL [51] 
or randomly packaged [52], but their function in virus lifecycle is unknown. Genomic 
RNA is specifically packaged into the virion through the interaction of  with the zinc 
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fingers of NC[53, 54]. However, where and when this interaction occurs is still unclear. 
In another retrovirus Rous Sarcoma Virus (RSV), there is evidence that some Gag 
proteins shuttle into the nucleus to pick up unspliced RNA that can act as genomic RNA 
[55]. Even though it is known that HIV-1 MA domain has a nuclear localization signal 
[36], the physiological relevance is debated [56]. On the other hand, tRNA
Lys
 
incorporation is independent of genomic RNA packaging. C-terminal domain of CA is 
thought to bind Lysyl-tRNA synthetase (LysRS) and this interaction is necessary for 
selecting tRNA
Lys
. In addition, GagPol, especially reverse transcriptase (RT) is important 
for stabilizing the interaction leading to efficient incorporation of the tRNA
Lys
 into the 
virion [57].  Once packaged, NC domain of Gag acts as a chaperone and facilitates the 
tRNA
Lys 
annealing to the primer-binding site on the viral RNA [58]. Gag-RNA binding 
also has a major role in assembly. It is thought that NC- bound RNA acts as a scaffold, 
concentrating Gag molecules in a single place, where they can multimerize efficiently. 
Even though genomic RNA is thought to provide this scaffolding function, cellular RNAs 
can also behave similarly and aid in higher-order multimerization of Gag [59]. MA can 
also interact with RNA [60-65] and this interaction may play a redundant role with NC-
RNA interaction in virus assembly and particle production [66]. It is, however, unknown 
which RNA is bound to MA, as there is no consensus sequence agreement between 
groups that have isolated RNAs bound to MA with higher affinity. In addition, the 
physiological role of this MA-RNA interaction is unclear.  
Site of HIV-1 assembly 
HIV-1 assembly occurs at the plasma membrane (PM) [67] or, in the case of 
macrophages, in deep invaginations of the PM called virus-containing compartments 
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(VCC). These compartments are connected to the cell surface via membrane-lined tubular 
conduits [68-70]. Endosomes were also proposed previously to serve as native sites for 
assembly of HIV-1 particles, as Gag was frequently observed in these compartments.  
However, most of the WT virus particles localized in these endosomal compartments are 
now thought to originate from endocytosis of particles already assembled at the PM 
[71](for reviews, see [72, 73]).  Consistent with the notion that endosomes do not 
constitute a native virus release pathway, redirecting Gag to endosomal compartments 
severely inhibits release of HIV-1 in HeLa, COS, and 293T cells perhaps because 
assembled particles are trapped in these compartments [71, 74-77]. It is therefore possible 
that the PM serves as the preferred site of HIV-1 assembly because it allows nascent 
particles to readily exit to the extracellular space. However, recent evidence suggests that 
at least in T cells, mutant Gag proteins targeted to the intracellular compartments can still 
be released as extracellular particles and are not necessarily trapped in these 
compartments [78]. Therefore, easy access to the extracellular space is unlikely to be the 
only reason that necessitates specific localization of HIV-1 Gag to the PM. Additional 
advantages that might be associated with virus assembly at the PM include lipid raft 
association and cell-cell transmission of the virus, both of which facilitate efficient 
replication of the virus. The focus of my thesis is to determine the molecular mechanisms 
by which Gag is specifically targeted to the PM. 
Gag membrane binding is driven by bipartite signal in MA 
MA is the membrane proximal domain of Pr55
Gag
 (Fig.1.4A). The first 104 amino 
acids of the MA form a compact globular domain consisting of five major -helices that 
are capped by a mixed three-stranded -sheet [79, 80]. MA is myristoylated at the amino-
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terminus and facilitates membrane binding of Gag [81]. In addition, a highly basic region 
(HBR) spanning residues 17-31 (Fig.1.4A), which is exposed and clustered around the 
mixed -sheet on the surface of MA, is important for efficient membrane binding and 
proper targeting of Gag to the PM [74-76, 82-84]. Mutagenesis studies suggest that the 
region spanning residues 84-88 is also important for PM localization of Gag [76, 85]. 
However, this region is buried within MA and hence it is likely that mutations in this 
region indirectly alter the HBR and affect Gag localization. Consistent with this 
hypothesis, a revertant of an MA mutant with a substitution in this region had a 
compensatory second site mutation in the MA HBR, suggesting that these regions are 
functionally linked [86].  Besides having determinants for membrane binding and proper 
targeting, MA, especially the HBR region, is also important for other processes in viral 
life cycle, such as envelope glycoprotein incorporation and several post-entry processes 
[for review see [61]]. MA HBR also interacts with RNA, but the physiological relevance 
of this interaction is unknown. Chapter III of this thesis focuses on this interaction as a 
potential regulator of Gag-membrane binding.  
The N-terminal myristoyl moiety is sequestered in the globular domain of MA 
Myristoylation is a process that occurs co-translationally, where a 14-carbon 
saturated fatty acid, myristic acid, is attached to the N-terminal glycine that is exposed 
after the first methionine is removed. The enzyme that catalyzes this reaction is the 
myristoyl-CoA: protein N-myristoyltransferase (NMT) [for detailed review see [87]]. In 
addition to the absolute requirement for Glycine at position 1 (numbering of residues in 
this thesis is based on the fact that glycine will be the first residue after the first 
methionine is removed), human NMT prefers polar residues at positions 2 and 3, large 
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hydrophobic at position 4, small polar residues such as serine at position 5 and lysine at 
position 6.  About 0.5 to 3% of eukaryotic proteins are thought to be myristoylated. These 
myristoylated cellular proteins are involved in many cell-signaling cascades and include 
protein kinases and phosphatases, cytoskeleton-associated proteins, calcium binding 
proteins, small G-proteins etc. In addition to the eukaryotic proteins, certain viral and 
bacterial proteins have also been shown to be myristoylated. As mentioned above, the 
MA domain of Gag is myristoylated at the N-terminus. Mutating the N-terminal glycine 
to alanine severely reduces membrane binding of Gag and inhibits virus particle release 
[74, 81, 85, 88, 89]. In addition, mutating MA residues 2-5 also reduces membrane 
binding and virus particle production, which is consistent with the idea that these residues 
are required for NMT recognition [86, 89].  
Differential membrane binding of the MA domain alone and of full-length Gag 
led to the hypothesis that a structural change in MA alters its myristate-mediated 
membrane binding [90-93]. According to the original hypothesis of myristoyl switch, the 
myristate moiety is sequestered in the MA globular domain, and upon Gag 
multimerization, a structural change exposes the acyl chain facilitating efficient 
membrane binding.  Consistent with this model, mutations of MA residues 6 and 7 were 
shown to inhibit myristate exposure [89, 94, 95], and certain other mutations or deletions 
in the MA globular domain were observed to enhance Gag membrane binding, 
presumably through inhibition of myristate sequestration [84, 89, 90, 92, 95, 96]. The 
presence of myristoyl switch was eventually demonstrated by NMR analysis [97]. In this 
study, MA was shown to exist as an equilibrium mixture of myristate-sequestered 
monomer and myristate-exposed trimer. Notably, this study observed that the myristoyl 
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moiety moves into or out of a hydrophobic cavity of MA in a manner coupled to MA 
trimerization without involving a drastic structural change of MA. Interestingly, C-
terminal addition of the CA sequence, which contains a dimerization domain, shifted the 
equilibrium toward the myristate-exposed trimeric state by increasing the self-association 
of otherwise low-affinity molecules. These results suggest a model in which Gag 
multimerization stabilizes MA trimerization thereby facilitating myristate exposure and 
membrane binding.   
Consistent with the multimerization-coupled myristoyl switch model, liposome or 
lipid monolayer binding studies showed that addition of the CA-derived dimerization 
domain to HIV-1 MA enhances its affinity for membranes [98, 99]. However, membrane 
binding of these Gag constructs was dependent on the presence of acidic phospholipids.  
Furthermore, similar observation was also obtained for RSV MA that lacks myristate 
[100].  Therefore, these studies suggest that multimerization-dependent enhancement of 
membrane binding is explained at least partly by the increased avidity of the whole Gag 
complex to the membranes via clustering of multiple HBRs and myristate moieties on 
MA. In addition to the avidity, virus particle formation could also partly account for 
enhanced membrane binding of full-length Gag in cells. Gag molecules within virus 
particles that remain on the cell surface are in effect irreversibly membrane-bound in 
fractionation experiments. Altogether, it is likely that the myristate exposure is not the 
sole reason for the difference between membrane binding of MA and that of full-length 
Gag [90-93]. Further in vivo and in vitro studies are required to sort out mechanisms 
contributing to the difference between membrane affinities of MA and full-length Gag.  
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Gag multimerization is not the sole trigger for exposure of the myristoyl moiety. 
As detailed later, the interaction of the HBR with a PM-specific acidic lipid, 
phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] was also shown to trigger the 
myristate exposure for efficient membrane binding [101]. Interestingly, non-
myristoylated Gag that exists in a monomer-dimer equilibrium shifts to a monomer-
trimer equilibrium when inositol hexakisphosphate (IP6) is added to the solution [102]. 
As IP6 is structurally similar to the head group of PI(4,5)P2, it is conceivable that 
PI(4,5)P2 may also modulate trimerization of Gag, which is coupled to myristate 
exposure. In addition to PI(4,5)P2, binding of calmodulin to MA and pH changes were 
shown to cause structural changes that modulate the status of myristate exposure [103, 
104].  The role of calmodulin and pH changes in Gag membrane binding in cells has yet 
to be elucidated. 
The MA HBR binds acidic lipids 
Even though myristoylation is necessary, it is thought to be insufficient for 
efficient membrane binding of proteins [105, 106]. Myristoylation only provides 
reversible membrane binding, and a second signal is thought to be required for strong 
localization of the myristoylated protein to the membrane [106]. This second signal may 
be a polybasic cluster, a second acylation such as palmitoylation, or a protein-protein 
interaction that increases avidity of the protein complex. In the case of HIV-1 Gag, the 
interaction of the HBR with acidic lipids can provide such second signal[74].  
The PM is one of the cellular membranes that are rich in anionic lipids such as 
phosphatidylserine (PS) and phosphoinositides that preferentially localize on the 
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cytoplasmic leaflet [107]. This distinctive localization makes the cytoplasmic surface of 
the PM acidic. Proteins or protein domains with polybasic clusters on the surface, such as 
pleckstrin homology (PH) domains, myristoylated alanine-rich protein kinase C substrate 
(MARCKS), and k-ras, are targeted to this negatively charged surface where they interact 
with acidic lipids either in a lipid-head-group-specific manner or simply via electrostatic 
interactions [108-110]. Mutations within the polybasic cluster of these proteins 
significantly alter their PM binding and localization [111, 112]. Similarly, mutations in 
the MA HBR mislocalize Gag to intracellular compartments and reduce membrane 
binding of Gag [74-76, 82-84]. Structural and mutagenesis studies suggest that the HBR 
is exposed on the surface of the MA domain and interacts with acidic lipids [74, 79, 80, 
84, 98, 113]. Notably, however, Gag mutants lacking the MA globular domain except the 
N-terminal myristoylation signal can still bind membranes and release virus, suggesting 
that the HBR is important for efficient membrane binding only in the context of full-
length MA [96, 114-117].  
Phosphatidylinositol-(4,5)-bisphosphate is important for PM targeting of Gag 
As alluded to earlier, recent studies have shown that the basic residues in the HBR 
interact with the acidic phospholipid, PI(4,5)P2 [84, 101, 118, 119]. PI(4,5)P2 belongs to a 
family of phospholipids called phosphoinositides. These lipids are derivatives of 
phosphatidylinositol and have a hydrophobic diacylglycerol backbone esterified to a 
polar inositol head group that can be phosphorylated at three of the five hydroxyl residues 
(Fig. 1.4b). Thus, seven different phosphatidylinositol phosphates (PIPs) are formed, 
which vary in the number and position of phosphates on the inositol ring [120]. Various 
cellular proteins with basic residues on the molecule surface have different affinities and 
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specificities to the head groups on phosphoinositides [109]. Through the recruitment of 
these proteins in either a head-group-specific or simply a charge-dependent manner, PIPs 
control several important cellular processes including membrane fusion, budding, and 
actin dynamics [121]. Notably, PIPs themselves are spatially and temporally regulated by 
the action of kinases and phosphatases that add or remove phosphate on the inositol ring, 
respectively. The predominant localization of various phosphoinositides is shown in 
Fig.1.5. Among the PIPs, PI(4,5)P2 is the most abundant and is specifically localized on 
the cytoplasmic leaflet of the PM.  
The first clue for the role of PIPs in HIV-1 assembly came from an in vitro 
assembly study where both RNA and inositol pentakisphosphate (IP5) were shown to be 
required for Gag to form a proper virus-like structure [122]. IP5 is an inositol derivative 
structurally related to the head group of PI(4,5)P2.  The requirement for PI(4,5)P2 in HIV-
1 assembly became evident from the study in which cellular PI(4,5)P2 was depleted or 
mislocalized in HeLa cells, either using phosphatidylinositol polyphosphate 5 
phosphatase  type IV (5ptaseIV), which removes D-5 phosphate from the inositol head 
group [123] or constitutively active Arf 6, which induces PI(4,5)P2-enriched intracellular 
vesicles, respectively [124, 125]. Both methods of PI(4,5)P2 perturbation mislocalized 
Gag to internal compartments and significantly reduced virus particle release [77]. 
Subsequently, several in vitro structural and biochemical studies, including the work in 
Chapter II of this thesis showed that Gag interacts with PI(4,5)P2 via basic residues in the 
HBR [101, 118, 119, 126]. Shkriabai, et al. examined the accessibility of lysines in non-
myristoylated full-length Gag proteins after Gag was mixed with a water-soluble 
analogue of PI(4,5)P2 that has short acyl chains and found two lysines in MA HBR as 
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potential PI(4,5)P2 binding site [119]. Saad, et al. determined the structure of the complex 
between myristoylated MA and a water-soluble PI(4,5)P2 analogue using NMR and 
identified binding of PI(4,5)P2 to MA as a trigger for myristate exposure [101]. Notably, 
this study not only showed interactions between the acidic head group of PI(4,5)P2 and 
basic amino acids in the HBR but also revealed the interaction between 2’ acyl chain and 
a hydrophobic pocket that is normally occupied by the myristoyl moiety . While these 
studies utilized the water-soluble analogues of PI(4,5)P2, the work in Chapter II of this 
thesis demonstrated that full-length myristoylated Gag binds to membrane-associated 
PI(4,5)P2 that contains native-length acyl chains  and that this interaction is important for 
efficient membrane binding of Gag in cells[118]. 
Gag and host vesicular trafficking pathways 
It is still unclear how Gag reaches the PM where it can interact with PI(4,5)P2. 
Several endosomal trafficking proteins have been implicated in the transport of Gag to 
the PM. Inhibiting interaction of Gag with adaptor proteins AP-1 or AP-3 blocks virus 
particle production and relocalizes Gag [127, 128]. Similarly siRNA knockdown of Rab9 
[108] and a kinesin motor KIF4 also causes accumulation of Gag in intracellular 
compartments and inhibits virus particle production [129]. Several other proteins like 
Golgi-localizing, gamma-adaptin ear homology domains (GGAs), ADP-ribosylation 
factors (ARFs) and AP-2 have also been shown to modulate the assembly process [130, 
131]. Thus, it is possible that Gag uses existing host vesicular trafficking pathway or 
multiple pathways to get to the PM. Further research is needed to pinpoint which 
pathway is predominantly used. 
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Overview of thesis 
 The work presented in this thesis illustrates the molecular determinants for PM 
association of Gag. Chapter II determines how PI(4,5)P2 is important for efficient 
membrane binding of Gag in addition to PM targeting of Gag. Chapter III demonstrates 
how MA HBR utilizes opposing regulatory mechanisms for facilitating membrane 
binding of Gag. The basic residues in the HBR not only facilitate membrane binding by 
interacting with PI(4,5)P2 but also inhibit non-specific membrane binding via 
sequestration of myristate and binding to RNA. Chapter IV discusses the results of 
chapter II and III along with the future directions for the project and describes some of 



















 Fig.1.1. HIV Genome Organization. HIV has 3 major genes, gag, pol and 
env that are common to all retroviruses.  In addition HIV also has 6 accessory genes: tat, 
rev, vpu, vpr, vif and nef. Completely spliced RNAs around 2kb encode for Tat, Rev and 
Nef. Once Rev is synthesized to sufficient amounts, it assists the transport of unspliced 
and singly spiced RNAs into the cytosol. Singly spliced RNAs around 4kb encode Env, 
















Fig. 1.2. HIV Life Cycle. HIV Env binds the cellular receptor CD4 and coreceptors 
CCR5 or CXCR4 and mediates fusion between cell membrane and viral membrane. This 
release the core into the cytosol, where the viral RNA is reverse transcribed into DNA. 
The DNA is then transported into the nucleus where it integrates with the cellular 
chromosome. Once integrated, the DNA is called provirus and behaves like a cellular 
gene and is transcribed and translated. Once the structural protein Gag is made, it initiates 
viral assembly on the plasma membrane. Other viral proteins depicted at the assembly 
site are GagPol, which has all the viral enzymes and Env, which uses secretory pathway 
to reach the assembly site. RNA transcribed from the provirus can also act as genomic 
RNA and a dimer of this genomic RNA is picked up by Gag during assembly. Once 
released from the cell, the viral protease becomes active and cleaves all the viral 
polyproteins leading to a structural change in the virus. The virus then becomes infectious 




Fig. 1.3. HIV-1 Gag domain structure and the assembly process. Gag synthesized as a 
polyprotein Pr55
Gag
 is the structural protein of HIV-1. As defined by the viral protease 
cleavage, it has 4 major proteins: Matrix (MA), Capsid (CA), Nucleocapsid (NC) and p6. 
In adidition it has two spacer peptides (SP1 and SP2). HIV-1 assembly is a multi-step 
process that includes targeting to the site of assembly, membrane binding and 
multimerization and eventual release into the extracellular space where virions matures 
into a fully infectious particle. Gag polyprotein is sufficient for assembly as there are 
functional domains that mediate each step of the assembly process. MA is important for 
targeting, membrane binding and Env incorporation. CA and NC are important for 
multimerization. NC also mediates viral RNA incorporation. p6 recruits cellular proteins 
that mediate release of the virus. 
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Fig. 1.4. Bipartite signal in MA domain of Gag and PI(4,5)P2 structure. A). 
Schematic representation and NMR structure showing the bipartite membrane-binding 
signal within matrix domain (yellow) of Gag.  Both the N-terminal myristoyl moiety 
(green) and the highly basic region (blue) are important for membrane binding of Gag. 
Structural information in the right panel is obtained from PDB database ID: 1UPH (Ref 
97)  B). PI(4,5)P2 structure. PI(4,5)P2 has a polar inositol head group, which is 
phosphorylated at D-4 and D-5 on the inositol ring. The acyl chains of PI(4,5)P2 found 
commonly in cells are saturated stearic acid at position 1’ and unsaturated arachidonic 







Fig.1.5. Sub-cellular localization of phosphoinositides. Different phosphoinositides 
have different sub-cellular localization within the cell due to the action of kinases and 
phophatases that add or remove phosphates on the inositol headgroup. Predominant 
localization of 5 different phosphoinositides is shown. PI(4,5)P2 and PI(3,4,5)P3 are on 
the plasma membrane, PI4P is in Golgi, PI3P is in the early endosomes (EE), PI(3,4)P2 is 
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Interaction between the HIV-1 Gag matrix domain and phosphatidylinositol-(4,5)-
bisphosphate is essential for efficient Gag-membrane binding 
  
ABSTRACT 
 HIV-1 particle assembly mediated by the viral structural protein Gag occurs 
predominantly on the plasma membrane (PM).  Although it is known that the matrix 
(MA) domain of Gag plays a major role in PM localization, molecular mechanisms that 
determine the location of assembly remain to be elucidated. We observed previously that 
overexpression of polyphosphoinositide 5-phosphatase IV (5ptaseIV) that depletes PM 
phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] impairs virus particle production, and 
redirects processed Gag to intracellular compartments. In this study, we examined the 
impact of PI(4,5)P2 depletion on the subcellular localization of the entire Gag population 
using Gag-fluorescent protein chimeras. Upon 5ptaseIV overexpression, in addition to 
perinuclear localization, Gag also showed a hazy cytosolic signal, suggesting that 
PI(4,5)P2 depletion impairs Gag-membrane binding. Indeed, Gag was less membrane-
bound in PI(4,5)P2-depleted cells, as assessed by biochemical analysis. These 
observations are consistent with the hypothesis that Gag interacts with PI(4,5)P2. To 
examine a putative Gag interaction with PI(4,5)P2, we developed an in vitro binding 
assay using full-length myristoylated Gag and liposome-associated PI(4,5)P2. Using this 
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assay, we observed that PI(4,5)P2 significantly enhances liposome binding of wild type 
Gag.  In contrast, a Gag derivative lacking MA did not require PI(4,5)P2 for efficient 
liposome binding.  To analyze the involvement of MA in PI(4,5)P2 binding further, we 
examined MA basic amino acid substitution mutants. These mutants, previously shown to 
localize in perinuclear compartments, bound PI(4,5)P2-containing liposomes weakly. 
Altogether, these results indicate that HIV-1 Gag binds PI(4,5)P2 on the membrane and 
that the MA basic domain mediates this interaction. 
 
INTRODUCTION 
Retroviral particle production is a complex multistep process mediated by a viral 
structural protein, Gag. HIV-1 Gag is synthesized as a precursor polyprotein, Pr55
Gag
. 
This precursor polyprotein consists of four major domains which, upon virus release, are 
cleaved by the viral protease (PR) to generate the mature Gag proteins: p17 matrix (MA), 
p24 capsid (CA), p7 nucleocapsid (NC), and p6. In addition, Pr55
Gag
 contains two spacer 
peptides SP1 and SP2 [1-3]. MA, which constitutes the N-terminal domain of Pr55
Gag
, is 
important for Gag-membrane binding and targeting of Gag to the plasma membrane 
(PM). CA and NC promote Gag multimerization, and p6 is essential for the release of 
virus particles [1-3].  
  Membrane binding of HIV-1 Gag is mediated by two signals in MA: The N-
terminal myristic acid and conserved basic region between MA amino acids 17 and 31 [4-
6]. The myristate moiety is considered to be regulated by a mechanism termed a 
myristoyl switch [7-15]. In this model, the N-terminal myristate is normally sequestered 
in the MA globular domain, but a structural change exposes myristate and enhances Gag-
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membrane binding. The patch of conserved basic residues likely contributes to membrane 
binding by interacting with acidic phospholipids in the inner leaflet of the PM [5, 16, 17]. 
In addition, the MA basic domain is involved in specific localization of Gag to the PM. In 
HeLa and T cells, mutations in the basic domain of MA shift the Gag localization from 
PM to intracellular vesicles containing late endosomal marker proteins [18-22]. In 
apparent contrast to HeLa and T cells, in macrophages, even when wild type (WT) Gag is 
expressed, the virus particles localize primarily at compartments positive for late 
endosomal markers [22-25]. However, these compartments, which first appeared to be 
internal, were later shown to be invaginations of the PM [26, 27]. Moreover, even in 
macrophages, a population of Gag was clearly observed at the cell surface, especially at 
early time points [28]. This specific localization of Gag to the PM or PM-related 
compartments suggests that host cellular factors play a role in determining the site of 
virus assembly.  
Many cellular proteins that bind the PM have membrane targeting sequences, 
such as pleckstrin homology (PH) domains. These domains are known to have clusters of 
basic amino acids that interact with negatively charged lipids collectively known as 
phosphoinositides [29-31]. Different phosphoinositides localize in different subcellular 
membranes, thereby influencing the location of proteins to which they bind [32, 33]. 
Phosphatidylinositol (4,5) bisphosphate [PI(4,5)P2] is concentrated primarily on the 
cytoplasmic leaflet of the PM, which is also the site where Gag assembles in most cell 
types. As mentioned above, Gag also contains a patch of basic amino acids that are 
important for PM localization. Furthermore, IP5 and IP6, which are structurally similar to 
PI(4,5)P2, were shown to interact with Gag in in vitro Gag assembly studies [34, 35]. 
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Altogether, this information led to the hypothesis that PI(4,5)P2 plays a role in PM 
localization of Gag through interaction with the MA basic amino acids. 
Previously, we showed that perturbing PM PI(4,5)P2 in HeLa cells markedly 
reduces virus production. This was demonstrated using two different approaches: 
overexpression of polyphosphoinositide 5-phosphatase IV (5ptaseIV) and a constitutively 
active ADP-ribosylation factor 6 (Arf6) mutant, Arf6/Q67L [36]. Overexpression of 
5ptaseIV reduces cellular PI(4,5)P2 levels by hydrolyzing the phosphate group at the D5 
position of the inositol ring [37], whereas expression of Arf6/Q67L induces PI(4,5)P2-
enriched vesicles within the cytoplasm [38, 39]. Altering PI(4,5)P2 levels by 5ptaseIV 
overexpression drastically reduced virus release efficiency when compared to cells 
expressing 5ptaseIV 1 mutant that lacks the functional phosphatase domain. In addition, 
in 5ptaseIV-overexpressing cells, mature Gag relocalized from the PM to CD63-positive 
compartments. Expression of Arf6/Q67L also reduced virus release efficiency. In this 
case, Gag was retargeted to newly induced PI(4,5)P2-enriched vesicles. These results 
support the model that PI(4,5)P2 promotes or stabilizes the binding of Gag to the PM by 
interacting with Gag. 
Recently, two studies addressed the question of whether Gag interacts with 
PI(4,5)P2[7, 40].  One study examined the accessibility of lysines after Gag is mixed with 
PI(4,5)P2. They identified two lysines at MA residues 29 and 31 as potential PI(4,5)P2- 
interacting amino acids. Interestingly, we have observed previously that the mutations at 
these MA residues relocalize Gag from the PM to compartments positive for late 
endosome markers in HeLa cells [20, 22]. The other group determined the structure of a 
complex between MA and PI(4,5)P2   using nuclear magnetic resonance (NMR). As is 
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often observed for interactions between PI(4,5)P2 and other proteins, in this structure, the 
inositol head group of PI(4,5)P2 was in direct contact with several basic residues in MA, 
although Lys 29 and 31 were not found to be involved.  Strikingly, in addition to the head 
group, the 2’ fatty acid chain of PI(4,5)P2 also binds to MA at a hydrophobic cleft.  
Furthermore, binding of PI(4,5)P2 to MA increased the exposure of the myristate moiety. 
Based on these findings, the authors proposed that PI(4,5)P2 not only acts as a membrane 
anchor for Gag, but also as a trigger for myristate exposure. Altogether, results from 
these studies are consistent with the model that Gag binds PI(4,5)P2 directly during virus 
assembly. 
However, two major caveats apply to these studies. First, because all the 
components need to be soluble in the approaches used, both studies used water-soluble 
PI(4,5)P2 with short acyl chains, which does not accurately represent the natural PI(4,5)P2 
found in the cells. Secondly, both studies used Gag derivatives that are unable to drive 
virus assembly in cells: isolated MA and MACA were used in the NMR study, and non-
myristoylated Gag was analyzed in the lysine accessibility experiments. Thus, it remains 
to be determined whether the Gag-PI(4,5)P2 interaction occurs in a physiologically 
relevant environment. 
In this study, we analyzed the overall membrane binding ability of Gag in control 
and PI(4,5)P2-depleted cells using microscopy and an equilibrium flotation assay. The 
data indicate that PI(4,5)P2 is important for general membrane binding as well as PM 
localization, supporting the hypothesis that Gag and PI(4,5)P2 interact. To determine 
whether Gag interacts with PI(4,5)P2 in a more defined system, we developed an in vitro 
liposome-binding assay in which full-length myristoylated Gag and PI(4,5)P2 with 
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natural-length acyl chains were used. Using this assay, we analyzed both WT and MA 
domain mutants for their ability to bind liposomes with varied amounts of PI(4,5)P2. Our 
results demonstrate that full-length myristoylated Gag binds membrane-associated 
PI(4,5)P2 and that this interaction mediated by the MA basic amino acids is important for 
Gag-membrane binding. We also demonstrate that efficient Gag membrane binding and 
Gag localization to the PM are separable processes that each require cellular PI(4,5)P2. 
 
MATERIALS AND METHODS 
Cells and Plasmids 
HeLa cells were cultured and maintained as described previously [41]. The HIV-1 
molecular clone pNL4-3 was described previously [42]. Molecular clones encoding Gag-
Venus (pNL4-3/GagVenus) and Gag-monomeric red fluorescent protein (mRFP1) 
(pNL4-3/GagmRFP) were constructed by replacing the SphI-SalI region of pNL4-3 with 
the corresponding regions of pHIV-1-GagvYFP3M and pHIV-1-GagmRFP, respectively. 
Both pHIV-1-GagvYFP3M and pHIV-1-GagmRFP were derived from pON-HIG [43] 
and express the full-length Gag fused to a glycine-rich hinge (PGISGGGGGILD) and a 
fluorescent protein. Additionally, these two constructs encode tat, rev, and nef, and 
contain a large deletion in pol and silent mutations that destroy the gag-pol frameshift site 
without changing the protein sequence of Gag. The fluorescent protein gene vYFP3M 
harbors mutations that enhance the monomeric property of the encoded protein (A206K, 
L221K, F223R) [44]. In this manuscript, this Venus YFP derivative is referred to as 
Venus for simplicity. The 5ptase expression plasmid pcDNA4TO/Myc5ptaseIV [37] and 
the 1 mutant [36] were previously described. The plasmids expressing 5ptaseIV under 
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the control of HIV-1 long terminal repeat (LTR) promoter in the presence of Tat (pHIV-
Myc5ptaseIV and pHIV-Myc5ptaseIV 1) were made by replacing the Lck gene within 
pHIVLck+ (a kind gift from Dr. K.Strebel) with sequences encoding either Myc-tagged 
full-length 5patseIV or the 1 mutant, respectively, from corresponding pcDNA 
plasmids. Molecular clones encoding Gag derivatives in which the initiation codon or the 
entire MA sequence was substituted with the sequence of the N-terminal 10 amino acids 
from Fyn Kinase [pNL4-3/Fyn(10)fullMA and pNL4-3/Fyn(10) MA, respectively] were 
constructed using PCR mutagenesis. pGEMNLNR, the in vitro expression plasmid for 
Gag, was made by inserting the Nar I-EcoR I fragment from pNL4-3 into the multiple 
cloning site of pGEM
®
-1 (Promega Corporation).  The derivatives of pGEMNLNR 
encoding MA mutants, pGEMNLNR/1GA, pGEMNLNR/29KE/31KE, 
pGEMNLNR/29KT/31KT, pGEMNLNR/Fyn(10)fullMA, and 
pGEMNLNR/Fyn(10) MA, were made by replacing the Gag sequence of pGEMNLNR 
with  those from pNL4-3 derivatives, pNL4-3/1GA [18], pNL4-3/29KE/31KE [20], 
pNL4-3/29KT/31KT [45], pNL4-3/Fyn(10)fullMA, and pNL4-3/Fyn(10) MA, 
respectively.  pNL4-3/Fyn(10)fullMA/GagVenus and pNL4-3/Fyn(10) MA/GagVenus 
were constructed by replacing the Gag sequence of pNL4-3/GagVenus with those from 
pNL4-3/Fyn(10)fullMA and pNL4-3/Fyn(10) MA, respectively.  A molecular clone 
encoding non-functional viral protease, pNL4-3/PR
-
, was described previously [46]. 
Transfection, Virus Release Assay, and Immunoblottinng  
Transfection, metabolic 
35
S labeling of transfected cells, and immunoprecipitation 
of viral proteins using HIV immunoglobulin (HIV-Ig; AIDS Reagent and Reference 
Reagent Program) were performed as described elsewhere [20, 22, 41]. Virus release 
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efficiency was calculated as previously described [36]. Immunoblotting was performed as 
described previously[47] using HIV-Ig, rabbit polyclonal anti-GFP (Clontech, Mountain 
View, CA), or rabbit polyclonal anti-DsRed (Clontech) as primary antibodies.  Detection 
of specific signals was performed using Super Signal West Pico chemiluminescence 
detection kit (Pierce, Rockford, IL). 
Immunostaining and Fluorescence Microscopy 
Fixation and immunostaining of HIV- expressing HeLa cells was performed as 
described previously [20, 36]. For quantitative analysis of Gag localization phenotypes, 
cells transfected with pNL4-3/GagVenus or its derivatives, or pNL4-3/GagmRFP, along 
with pHIV-Myc5ptaseIV or its 1 derivative, were fixed and immunostained for the 
presence of 5ptase expression with rabbit anti-Myc antibody (Santa Cruz Biotechnology 
Inc., Santa Cruz, CA). Images of 10 to 15 fields were recorded using a Nikon TE2000 
microscope, and cells positive for full-length 5ptaseIV or the 1 mutant were evaluated 
for Gag localization pattern. At least 100 5ptaseIV-positive, Gag-positive cells were 
examined for each condition. 
Cell-Based Membrane Binding Analysis 
HeLa cells expressing WT or Fyn(10)fullMA Gag, along with full-length 
5ptaseIV or the 1 mutant, were pulse-labeled with [
35
S] Met/Cys for 5 minutes and 
chased for 20 minutes. After sonication of labeled cells, the cell homogenates were 
subjected to a low-speed centrifugation to remove unbroken cells and the nucleus-
associated materials as pellets.  These pellets contain approximately 10% of total labeled 
Gag (data not shown) regardless of which Gag or 5ptaseIV constructs were expressed in 
the labeled cells.  The post-nuclear supernatants were collected and subjected to 
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membrane flotation centrifugation as previously described [14].  The top fractions 
containing membrane-bound materials, and also the bottom fractions containing non-
membrane-bound materials, were pooled and subjected to immunoprecipitation using 
HIV-Ig. Labeled Gag in fractions was quantified by phosphorimager analyses as 
described previously [48, 49]. 
Liposome Binding Assay 
Chloroform solutions of 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine 
(POPC), 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-[Phospho-L-serine] (POPS), and L- -
Phosphatidylinositol-4,5-bisphosphate(Porcine brain) (PI(4,5)P2), and powder forms of 1-
Stearoyl-2-Arachidonoyl-sn-Glycero-3-[Phosphoinositol-4,5-Bisphosphate] (Tri-
ammonium Salt), 1-Stearoyl-2-Arachidonoyl-sn-Glycero-3-[Phosphoinositol-3,5-
Bisphosphate] (Tri-ammonium Salt), 1-Stearoyl-2-Arachidonoyl-sn-Glycero-3-
Phosphoinositol-3,4,5-trisphosphate (Tetra-ammonium Salt) were purchased from Avanti 
Polar lipids Inc., Alabaster, AL. Either POPC and POPS, or POPC, POPS and one of the 
phosphoinositides, were mixed in a tube at ratios described in figure legends and the 
chloroform was evaporated using a nitrogen stream. The dried lipids (total 730 μg) were 
resuspended in 50 μl of cold 20 mM HEPES buffer (pH7.0) (HB), sonicated for 30 
minutes in a water bath sonicator at 4°C, and further incubated in a shaker at 4°C 
overnight [50-52]. 
In vitro translation of Gag was performed using TNT
®
 SP6 Coupled Reticulocyte Lysate 
System (Promega Corporation, Madison, WI). Twenty five μl of a reaction mixture that 
contains 12.5 μl of reticulocyte lysate was prepared with [35S] methionine and cysteine as 
instructed by the manufacturer, incubated for 30 minutes at 30°C, 5 μl of the liposome 
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suspension (total 73 μg of lipids) prepared as above were added, and further incubated for 
90 minutes in the presence of liposomes. 
Subsequently, the reaction was diluted to 200 μl using HB and mixed with 1 ml of HB 
containing 85.5% sucrose in an ultracentrifuge tube. This mixture was then layered with 
2.8 ml HB containing 65% sucrose and 1 ml HB containing10% sucrose, and centrifuged 
at 115,000  g at 4°C for 16 hours (Sorvall rotor AH-650, 35000 rpm). Five 1 ml 
fractions were collected from the top of each tube. The top two fractions represent 
liposome-bound Gag, and the bottom fractions represent non-liposome-bound Gag. The 
fractions were analyzed by SDS-PAGE, and the band intensity of Gag in each fraction 
was quantified using a phosphorimager. The amount of labeled Gag in the top two 
fractions versus the total amount of labeled Gag was calculated and is shown as liposome 
binding efficiency.  For Figs. 2.5, 2.6, and 2.9, the relative liposome binding efficiency 
for each condition was calculated in comparison to the binding efficiency of WT Gag 
with PI(4,5)P2-containing liposomes. 
Statistical Analysis 
The two-tailed Student’s t-test was performed using GraphPad Prism version 3.0cx for 
Macintosh, GraphPad software, San Diego, California (www.graphpad.com). The paired 
t-test was used for comparing the data within the same set of experiments. p values less 
than 0.05 were considered statistically significant. 
 
RESULTS 
Overexpression of 5ptaseIV relocalizes HIV-1 Gag to the perinuclear compartments 
and cytosol. 
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In a previous study, we used a monoclonal antibody against p17MA to show that 
overexpression of 5ptaseIV relocalizes Gag to perinuclear compartments [36]. However, 
this antibody recognizes only mature MA, but not Pr55
Gag
 [10]. To determine the 
localization of the whole population of Gag, in this study we used Gag tagged with Venus 
yellow fluorescent protein [53](GagVenus) or monomeric red fluorescent protein 
[54](GagmRFP). To examine the impact of 5ptaseIV overexpression on Gag localization, 
HeLa cells were transfected with either GagVenus or GagmRFP, along with 5ptaseIV or 
its derivative lacking a functional phosphatase domain (the 1 mutant), and analyzed 
with a fluorescence microscope (Fig. 2.1A, and data not shown).  In cells expressing the 
5ptaseIV 1 mutant, a majority of GagVenus and GagmRFP showed punctate PM 
localization as expected for WT Gag. When full-length 5ptaseIV was expressed, 
however, most Gag signals were detected either in perinuclear compartments or in the 
cytosol. To assess the effect of 5ptaseIV more quantitatively, cells expressing GagVenus 
or GagmRFP were counted and divided into three groups based on Gag localization: Gag 
localized to the PM, Gag predominantly in the intracellular compartments, or Gag only in 
the cytosol without PM or intracellular localization (Fig. 2.1B). The cells expressing the 
1 mutant of 5ptaseIV had Gag localized to the PM in more than half of the cells. Very 
few cells showed perinuclear localization. The remaining cells displayed only hazy 
cytosolic localization.  These Venus and mRFP signals likely represent full-length Gag 
tagged with the fluorescent proteins, as virtually no other protein species containing the 
fluorescent tags were detected by immunoblotting of cell lysates (Fig. 2.1C).   In contrast 
to cells expressing 5ptaseIV 1, cells expressing full-length 5ptaseIV had drastically 
increased hazy cytosolic localization and intracellular localization, whereas cells that had 
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PM localization were reduced to only 5% of total Gag-positive cells. These results 
indicate that, when cellular PI(4,5)P2 is depleted, Gag relocalizes not only to intracellular 
compartments as we have shown previously [36], but also to the cytosol. These data 
confirm the importance of PI(4,5)P2 in PM localization of Gag. In addition, the increase 
in the hazy cytosolic signal in 5ptaseIV-expressing cells suggests that PI(4,5)P2 might 
also be essential for total membrane binding of Gag. 
Overexpression of 5ptaseIV causes a Gag-membrane binding defect.  
To analyze more quantitatively whether PI(4,5)P2 depletion impairs membrane 
binding of Gag, we examined the membrane binding of WT Gag in HeLa cells 
expressing either 5patseIV or the 1 mutant, by equilibrium flotation centrifugation. The 
cells were pulse-labeled with [
35
S] Methionine-Cysteine for 5 minutes, and chased for 20 
minutes, and post-nuclear supernatants of cell homogenates were subjected 
to equilibrium flotation centrifugation. The labeled Gag in both top fractions (membrane-
bound) and bottom fractions (non-membrane-bound) was immunoprecipitated with HIV-
Ig and quantified by phosphorimager. We found that the membrane binding of Gag was 
significantly decreased when full-length 5ptaseIV was expressed compared to the 1 
mutant of 5ptaseIV (Fig. 2.2A & B). These results indicate that PI(4,5)P2 is not only 
important for plasma membrane localization but also contributes to general membrane 
binding of Gag.  A large part of membrane-bound Gag still detected in cells 
overexpressing 5ptaseIV may be a population associated with the intracellular 
membranes observed in Fig. 2.1.  Notably, we did not observe a significant reduction in 
the membrane binding of Fyn(10)fullMA Gag (Fig. 2.2A & B), a Gag derivative in which 
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the N-terminal myristoylation site is replaced by Fyn membrane binding signal 
containing one myristoylation and two palmitoylation sites. These data indicate that 
addition of a strong membrane binding signal to MA can reverse the membrane-binding 
defect imposed by PI(4,5)P2 depletion. 
The Presence of PI(4,5)P2 increases Gag binding to liposomes.  
 As described above, cellular PI(4,5)P2 depletion not only relocalized Gag from 
the PM to intracellular compartments, but also reduced the total membrane-binding 
ability of Gag. These results are consistent with the hypothesis that Gag interacts with 
PI(4,5)P2 directly. To test this hypothesis, we developed an in vitro system using 
liposomes that consist of phosphatidylcholine(PC), phosphatidylserine (PS) and varied 
amounts of  PI(4,5)P2. An in vitro transcription and translation coupled reaction with 
rabbit reticulocyte lysate was used to synthesize full-length myristoylated Gag in the 
presence of  [
35
S] methionine-cysteine. This in vitro Gag synthesis has been used 
successfully for studying Gag-membrane binding and assembly [5, 10, 11, 55-59]. After 
30 minutes of Gag synthesis, the reaction was mixed with liposomes and further 
incubated for 90 minutes. The liposome-bound Gag and non-liposome-bound Gag were 
separated by equilibrium flotation centrifugation. The amount of labeled Gag in each 
fraction was quantified using a phosphorimager, and the percentage of Gag bound to the 
liposomes versus total Gag was calculated. When the PI(4,5)P2 concentration in the 
liposomes was increased gradually, the liposome-bound Gag also increased (Fig. 2.3A & 
B), suggesting that the Gag-PI(4,5)P2 interaction mediates Gag binding to liposomes.   
In the experiments described above, the ratio between PC and PS was kept 
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constant (2:1) while the amounts of PI(4,5)P2 were gradually increased.  Therefore, it is 
possible that the enhanced Gag binding to liposomes in the presence of PI(4,5)P2 may be 
due to the increase in the overall negative charge of liposomes, not the increase in the 
PI(4,5)P2 concentration per se.  To address this possibility, we analyzed Gag binding to 
PC-PS liposomes containing elevated levels of PS.  As PI(4,5)P2 is likely trivalent or 
tetravalent in the negative charge under the conditions tested, whereas PS is monovalent 
[60], we examined liposomes containing 52 or 60 mol % PS that would bear equivalent 
levels of the negative charge as liposomes containing 30 mol% PS and 7.25 mol% 
PI(4,5)P2 used in Fig. 2.3A and B.  Liposomes with 52 or 60 mol % PS showed increased 
Gag binding compared to liposomes containing 30 mol % PS (Fig. 2.4A and B), 
suggesting that electrostatic interaction between Gag and lipids does play a role in Gag-
liposome binding.  Nevertheless, these high concentrations of PS were insufficient to 
mediate the high level of Gag binding observed with liposomes containing 30 mol% PS 
and 7.25 mol% PI(4,5)P2 (Fig. 2.4Aand B).  These results suggest that enhanced Gag 
binding to PI(4,5)P2-containing liposomes does not simply result from the increase in the 
overall negative charge of liposomes.   
PI(4,5)P2 may facilitate Gag binding due to the highly concentrated negative 
charge of its head group.  Alternatively, the configuration of phosphate residues may play 
a key role in the specificity of the Gag-PI(4,5)P2 interaction.  To evaluate these 
possibilities, we compared PI(3,5)P2 and PI(3,4,5)P3 with PI(4,5)P2 at 7.25 mol% for the 
ability to recruit Gag to liposomes containing 30 mol % PS.  We observed that PI(3,5)P2 
and PI(3,4,5)P3 substantially enhanced Gag binding to liposomes compared to the control 
liposomes. However, Gag binding to PI(3,5)P2-containing liposomes was consistently 
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less than that to PI(4,5)P2-containing liposomes. We did not observe significant 
difference between PI(4,5)P2 and PI(3,4,5)P3 (Fig. 2.4C and D).  It is of note that, using 
water-soluble phosphoinositides, Saad et al. observed that the isolated MA domain also 
binds PI(4,5)P2 and PI(3,4,5)P3 but not PI(3,5)P2[7].  These data suggest that not only the 
number but also the position of phosphates on the inositol head group affects the Gag-
phosphoinositide interaction.  Altogether, these results demonstrate that there is an 
interaction between the head group of PI(4,5)P2 and full-length Gag and that this 
interaction facilitates membrane binding of Gag.   
To confirm that the observed Gag binding to liposomes reflects the Gag-
membrane interaction in cells, we also examined, using liposome-binding assay, a non-
myristoylated Gag (1GA) that was previously shown to be defective in membrane 
binding in cell-based assays [4-6, 14, 15].  As shown in Fig. 2.5A, WT but not 1GA Gag 
was myristoylated in the in vitro translation system we used.  The 1GA mutant binds 
liposomes inefficiently even in the presence of 7.25 mol % PI(4,5)P2 (Fig. 2.5B and C). 
These results indicate that myristoylation is required for efficient Gag-liposome 
interaction. These results further demonstrate that, unlike assays using water-soluble 
PI(4,5)P2, the liposome-binding assay developed here is suited for examining the 
interaction between Gag and PI(4,5)P2 in the context of membrane binding. 
MA mediates Gag interaction with PI(4,5)P2. 
MA was shown previously to be important for both membrane binding and PM 
localization [1-3]. To assess the importance of MA in the interaction with PI(4,5)P2 in 
liposome-binding assay, we sought to delete the entire MA sequence. Since such MA 
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deletion removes the site for myristoylation that is indispensable for membrane binding, 
we instead used a Gag derivative that lacks the entire MA sequence but contains the N-
terminal 10 amino acids of the Fyn kinase, Fyn(10) MA Gag (Fig. 2.6A). This Fyn-
derived sequence is myristoylated and dually palmitoylated, thereby providing this Gag 
derivative with a high membrane affinity. As a control, we used Fyn(10)fullMA Gag 
(Fig. 2.6A), which retains the entire MA sequence following the Fyn-derived peptide.  As 
shown in Fig. 2.6B and C, liposome binding of Fyn(10)fullMA Gag was still augmented 
by PI(4,5)P2 as observed for WT Gag. However, when MA was deleted as in 
Fyn(10) MA Gag, Gag bound both control and PI(4,5)P2-containing liposomes with 
similar efficiences. These results demonstrate that MA confers dependence on PI(4,5)P2 
for liposome binding. 
PM localization and virus release efficiency of Fyn(10)fullMA Gag are still sensitive 
to 5ptaseIV overexpression. 
In contrast to the data obtained from the liposome-binding assay, in the cell-based 
membrane binding analysis, Fyn(10)fullMA Gag did not show any significant 
membrane-binding defect upon PI(4,5)P2 depletion (Fig. 2.2). In the case of WT Gag, 
5ptaseIV alters Gag localization to the PM in addition to reducing membrane binding.  
To investigate whether the PI(4,5)P2 dependence of Fyn(10)fullMA Gag for liposome 
binding is manifested as a defect in the PM localization, we analyzed the effect of 
5ptaseIV overexpression on localization of Fyn(10)fullMA GagVenus as in Fig. 2.1.  In 
5ptaseIV 1-expressing cells, Fyn(10)fullMA GagVenus was predominantly localized on 
the PM.  In cells overexpressing full-length 5ptaseIV, however, we observed that a 
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majority of Fyn(10)fullMA GagVenus was localized to intracellular compartments (Fig. 
2.7A and B).  These results indicate that, even though general membrane binding of 
Fyn(10)fullMA Gag is not affected in cells (Fig. 2.2), PM localization of this Gag 
derivative still requires cellular PI(4,5)P2.  To examine whether the altered Gag 
localization affects virus particle production, we examined the virus release efficiency of 
Fyn(10)fullMA Gag in 5ptaseIV-overexpressing cells. HeLa cells were transfected with a 
molecular clone encoding WT Gag or Fyn(10)fullMA Gag, along with an expression 
vector for either 5ptaseIV or the 1 mutant. The cell and viral lysates were 
immunoprecipitated with HIV-Ig after metabolic labeling, and the virus release efficiency 
was calculated.  Consistent with the altered localization of Gag, the virus release 
efficiency of Fyn(10)fullMA Gag as well as WT Gag was reduced when the cells express 
5ptaseIV(Fig. 2.8A and B).  These results indicate that cellular PI(4,5)P2 is required 
separately both for efficient membrane binding and PM localization of WT Gag. 
The liposome-binding assay showed no difference in binding of Fyn(10) MA 
Gag to control and PI(4,5)P2-containing liposomes (Fig. 2.6).  Therefore, we predicted 
that Gag localization and virus particle production of Fyn(10) MA Gag would be 
insensitive to 5ptaseIV overexpression in contrast to Fyn(10)fullMA.  Venus-tagged 
Fyn(10) MA Gag localized not only to the PM but also to intracellular vesicles in a 
majority of cells expressing 5ptaseIV 1 (Fig. 2.7A and B).  This promiscuous 
localization of Fyn(10) MA Gag, which was also observed previously for a similar Gag 
derivative lacking MA[61], underscores the importance of MA in specific Gag 
localization to the PM.  Notably, overexpression of full-length 5ptaseIV did not cause a 
readily detectable qualitative difference in Gag localization (Fig. 2.7A and B).  
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Nevertheless, 5ptaseIV overexpression significantly reduced Fyn(10) MA Gag virus 
release efficiency (Fig. 2.8A and B).  We are currently investigating the possibility that 
cellular PI(4,5)P2 might play an additional role in HIV-1 particle production. 
Matrix basic domain mutants display a PI(4,5)P2 binding defect in vitro. 
As described in the introduction, MA contains a basic amino acid cluster that was 
previously shown to play an important role in plasma membrane localization of Gag [18-
21]. To see if the basic residues in this cluster facilitate the MA-PI(4,5)P2 interaction, we 
tested the mutants in which lysines were replaced with either glutamic acid (29KE/31KE) 
or threonine (29KT/31KT) at MA residues 29 and 31, using in vitro liposome binding 
assay. Full-length Gag with WT MA or with MA mutations 29KE/31KE or 29KT/31KT 
were synthesized using  in vitro translation system, and were allowed to interact with the 
control liposomes or liposomes containing PI(4,5)P2. There was a 2.5-fold decrease in 
binding of both mutants to PI(4,5)P2-containing liposomes when compared to WT Gag 
(Fig. 2.9A & B). Both of these Gag mutants were previously shown to localize in 
intracellular vesicles using immunoflorescence microscopy [20, 22]. These results 
indicate that the efficient interaction of Gag with PI(4,5)P2 requires basic amino acids in 
the MA domain, especially residues at positions 29 and 31, and suggest that this 
interaction is important for the plasma membrane localization of Gag. 
DISCUSSION 
We have shown previously that PI(4,5)P2 is essential for plasma membrane 
localization of HIV-1 Gag. In this study, using microscopy (Fig. 2.1) and biochemical 
methods (Fig. 2.2), we observed that PI(4,5)P2 is not only important for PM localization 
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but also contributes to overall membrane binding of HIV-1 Gag. Using a liposome 
binding assay, we further demonstrated that the MA domain of Gag and PI(4,5)P2 interact 
with each other. Recently, using different approaches, two groups [7, 40] reported 
evidence supporting a possibility that MA and PI(4,5)P2 interact directly.  By solving the 
structure of the MA-PI(4,5)P2 complex by NMR, one of these studies provided detailed 
information on the molecular contacts between MA and PI(4,5)P2 at a high resolution [7].  
As described in the Introduction, however, whether the interaction observed in these 
studies is physiological was unknown. In the liposome binding assay described in this 
report, we used membrane-associated PI(4,5)P2 with natural-length acyl chains. 
Furthermore, the Gag synthesized by the in vitro translation system is full-length, 
myristoylated Gag precursor that is capable of driving HIV assembly in cells. Thus, this 
assay allowed us to examine the interaction between Gag and PI(4,5)P2 using 
components relevant to virus assembly in cells. Using this assay, we observed that only 
when PI(4,5)P2 is present does Gag bind efficiently to the liposomes. Altogether, these 
results demonstrate that the full-length HIV-1 Gag indeed interacts with membrane-
associated PI(4,5)P2, and that this interaction contributes to efficient Gag-membrane 
binding in cells. 
 Using the liposome-binding assay, we observed an increase in the level of Gag 
binding when more PI(4,5)P2 was present in the liposomes. Though there was negligible 
binding to liposomes containing up to 2 mol % PI(4,5)P2, increasing the PI(4,5)P2 level to 
3.5 mol % or more enhanced Gag binding significantly. It has been shown that 5 mol % 
PI(4,5)P2 was required for liposome binding of cellular PI(4,5)P2-binding proteins 
including ezrin, myosin VI and gelsolin [62-64]. As PI(4,5)P2 is thought to be present at 
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1-1.5 mol % of total PM lipid in cells [65-67], one might pose a question that the binding 
seen in the presence of higher levels of this lipid may not be physiologically relevant. 
However, several points bear consideration. First, the PI(4,5)P2 concentration in the PM 
has been determined using erythrocytes [65-67]. These cells have a unique cytoskeleton 
structure [68-70] and lack the regular endocytosis function [71]. As actin cytoskeleton 
rearrangement and endocytosis are two major PI(4,5)P2-regulated cellular functions in 
other cell types [60, 72-74], PI(4,5)P2 levels in erythrocytes may differ from those in 
other cell types. Second, it is important to point out that liposomes used in this assay are 
not completely representative of the PM, especially with regard to membrane 
microdomain structures. They lack cholesterol and other lipids that may form lipid rafts, 
which are shown to be important for HIV-1 assembly in cells [48, 75-80], particularly at 
the step of Gag-membrane binding [48]. Furthermore, it has been proposed that PI(4,5)P2 
may be sequestered to form microdomains and induce raft-like structures [81-83], which 
would lead to higher local PI(4,5)P2 concentrations. Finally, in cells, PI(3,4,5)P3 might 
also support the PM binding of Gag. A recent paper has shown that proteins with 
polybasic clusters dissociated from the PM only when both PI(4,5)P2 and PI(3,4,5)P3, but 
not PI(4,5)P2 alone, were depleted [84]. This may also be the case for HIV-1 Gag, which 
is sensitive to 5ptaseIV overexpression. Since 5ptaseIV removes the D5-phosphate not 
only from PI(4,5)P2, but also from PI(3,4,5)P3 [37], the defect observed in 5ptaseIV-
expressing cells could be due to dephosphorylation of both phosphoinositides.  Consistent 
with this possibility, the NMR study [7] showed that HIV-1 MA bound soluble PI(4,5)P2 
and PI(3,4,5)P3 with equal affinity. A substantial interaction was also observed between 
full-length Gag and membrane-associated PI(3,4,5)P3 in the current study.  Thus, 
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PI(3,4,5)P3 might also contribute to the membrane binding of Gag along with PI(4,5)P2 in 
cells. 
Even if PI(4,5)P2 is not available for Gag binding, addition of the efficient 
membrane binding signal derived from Fyn kinase to the N-terminus of Gag would be 
expected to allow Gag to bind any liposomes with equal efficiency. However, when 
Fyn(10)fullMA Gag was analyzed using the liposome-binding assay, binding of this Gag 
derivative to control liposomes was weak, and the presence of PI(4,5)P2 augmented the 
binding several fold (Fig. 2.6).  Notably, binding to control liposomes was enhanced 
when MA was removed as observed with Fyn(10) MA Gag that bound control and 
PI(4,5)P2-containing liposomes with a similar efficiency (Fig. 2.6).  Thus, MA renders 
Gag-liposome binding dependent on PI(4,5)P2. We speculate based on these data, and a 
recent report [85], that MA in the context of full-length Gag might have a negative effect 
on liposome binding, which may be eliminated by the MA-PI(4,5)P2 interaction. In the 
absence of MA, this negative effect no longer exists, hence Fyn(10) MA Gag binds both 
control and PI(4,5)P2-containing liposomes efficiently. In contrast to the liposome 
binding assay, where there is only a limited number of membrane components, the cell-
based assay showed that Fyn(10)fullMA Gag binds membranes well, even in 5ptaseIV-
expressing cells (Fig. 2.2). This difference may be due to cellular components that are 
absent from liposomes. These factors might reduce the suppressive effect imposed by 
MA to a level low enough for the Fyn sequence to overcome.  This difference illustrates 
that the defined nature of lipid membrane used in the liposome-binding assay allows the 
contribution of PI(4,5)P2 to be evaluated in the absence of other membrane factors that, in 
the cell, can contribute to Gag-membrane binding.  
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In the liposome-binding assay described in this report, very little Gag associated 
with liposomes in the absence of PI(4,5)P2, even though more than 30 mol % of the 
liposomes consist of another acidic lipid, PS.  In contrast, a number of groups have 
observed that PS can support liposome binding of Gag in the absence of PI(4,5)P2 [5, 86-
90].  Some studies used a very high level of PS (e.g., PC:PS at a 1:2 ratio), which may 
account for the efficient PS-mediated membrane binding (discussed below).  Dalton et al. 
showed recently, however, that myristoylated HIV-1 MA efficiently binds to PC:PS (2:1) 
liposomes [87].  This discrepancy can be accounted for by differences in experimental 
systems.  One such difference is that Dalton et al. observed efficient binding of 
myristoylated MA or its derivative fused with CA C-terminal domain (MA-CACTD) to 
PS using much higher concentrations of the proteins than obtained in our assay.  In this 
way, they were able to measure a weak interaction between MA and PS.  In addition, a 
high concentration of Gag likely facilitates Gag multimerization, thereby increasing its 
avidity for membrane.  Indeed, Dalton et al. found that dimerization of MA-CACTD 
significantly enhances binding to PS-containing liposomes.  Whether Gag forms 
multimers under the conditions we used in our assay is currently unknown.  Second, the 
use of MA (or MA-CACTD) versus full-length Gag may also contribute to the difference 
in the PS interaction.  It is possible that the structure of isolated MA and the MA domain 
of full-length Gag may be not identical and that such conformational differences may 
affect the affinity for PS.  It was recently proposed that full-length Gag adopts a folded 
conformation in which MA and NC are in close proximity [91].  In the context of full-
length Gag, such a folded conformation may restrict the access of PS to the MA basic 
domain, which is freely accessible for PS in isolated MA or MA-CACTD.  Lastly, yet 
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another important difference is that, in our experiments, components of rabbit 
reticulocyte lysate used for synthesizing Gag were present during incubation of Gag with 
liposomes, whereas Dalton et al analyzed liposome binding of purified proteins in the 
absence of other cellular components.  Thus, in our system, negatively charged molecules 
such as IP6 and RNA, or positively charged molecules such as polyamines, both of which 
are present in mammalian cells, may interfere with the weak electrostatic interaction 
between Gag and PS.  Indeed, both IP6 and RNA were previously shown to bind MA 
[35, 92]. Altogether, we consider our in vitro assay as an approach complementary to 
existing ones in that it focuses on relatively strong interactions between Gag and 
membrane lipids, which overcome the interference by charged molecules present in 
mammalian cells. 
Even in our liposome binding assay, elevating the fraction of PS from 30 mol % 
to 52 or 60 mol % augmented Gag binding (Fig. 2.4A and B).  However, liposomes 
containing 7.25 mol % PI(4,5)P2 along with 30 mol % PS allowed more Gag binding than 
those containing 60 mol % PS (Fig. 2.4A and B), suggesting that the high charge density 
of PI(4,5)P2 plays a key role in Gag binding.  These data are largely consistent with the 
computational work of Murray et al [93], in which an electrostatic interaction was shown 
to determine the MA-membrane interaction. In this modeling study, when PI(4,5)P2 was 
present in the lipid bilayer, it significantly increased the electrostatic potential due to its 
high negative charge density, thus enhancing membrane binding of Gag [93]. Compared 
with PI(4,5)P2, however, PI(3,5)P2 was consistently less efficient in facilitating Gag-
liposome binding (Fig. 2.4C and D).  These findings, in agreement with the NMR study 
[7], suggest that, in addition to a high density of negative charge, a specific configuration 
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of phosphates on the inositol head group may play a role in the preferential interaction of 
Gag with PI(4,5)P2.  
Previously, we have observed that mutations at MA residues 29 and 31 within the 
highly basic sequence relocalized Gag from the PM to compartments positive for late 
endosome markers in HeLa and T cells. Using the liposome-binding assay, we observed 
that the 29KE/31KE Gag interacts less efficiently with PI(4,5)P2-containing liposomes 
than WT Gag. This effect is not simply due to a drastic change of charge from positive to 
negative, since the 29KT/31KT Gag, in which the same lysine residues are substituted 
with neutral amino acids, showed a similar level of reduction in binding to PI(4,5)P2-
containing liposomes.  It is also unlikely that these mutations caused a major 
conformational change that in turn resulted in the reduced binding to PI(4,5)P2-
containing liposomes, as Gag derivatives containing these amino acid changes are 
capable of forming virus particles with apparently a normal morphology at intracellular 
vesicles [18, 20].  Interestingly, Shkriabai et al. observed that the same lysine residues 
were masked from solvent when water-soluble PI(4,5)P2 was added to non-myristoylated, 
but full-length Gag [40].  In contrast, the NMR study performed using isolated MA in 
complex with PI(4,5)P2 did not show an interaction of MA residues 29 and 31 with 
PI(4,5)P2 [7]. This difference in the residues involved in PI(4,5)P2 interaction may be due 
to differences in  the conformation of the MA domain of Gag versus mature MA. We are 
currently examining the role of CA and NC domains in PI(4,5)P2-dependent liposome 
binding. These experiments will also likely provide insights into the ability of PS to 
support the MA-liposome binding discussed above. It is of note that the binding of the 
mutants 29KE/31KE and 29KT/31KT to PI(4,5)P2-containing liposomes was not totally 
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abolished, suggesting that there might be other basic amino acids playing a role in the 
Gag-PI(4,5)P2 interaction. The analysis of other basic MA amino acid mutants for their 
ability in binding PI(4,5)P2 is described in chapter III. 
One possible caveat of the liposome binding assay developed and used in this 
report might be the non-uniformity of liposomes. PI(4,5)P2 is not as soluble in 
chloroform as other lipids [94]. Therefore, in the procedure we used to prepare 
liposomes, this differential solubility may lead to non-uniform mixing of lipids, which 
may in turn result in variable percentages of PI(4,5)P2 in each individual liposome.  In 
addition, as discussed above, reticulocyte lysates present in the assay likely contain 
molecules that modulate the Gag-PI(4,5)P2 interaction.  Therefore, this assay should not 
be used to determine the affinity of Gag for PI(4,5)P2.  Nonetheless, the assay described 
here will be valuable in investigating requirements for the Gag-phosphoinositide 
interaction. 
In summary, we have shown that full-length Gag binds to PI(4,5)P2 associated 
with membranes under conditions relevant for virus assembly in cells, and this MA-
mediated interaction is important for efficient membrane binding of Gag. We also 
confirmed that, apart from membrane binding, cellular PI(4,5)P2 is also important for PM 
localization of Gag. Due to the continuous need for new drugs against HIV-1, it is 
important to look at interactions between viral proteins and cellular factors like PI(4,5)P2 
as potential drug targets. Although manipulation of cellular PI(4,5)P2 may not be a viable 
anti-retroviral strategy because of the physiological importance of this lipid in cells, 
inhibitors that block Gag binding to PI(4,5)P2 could perhaps be developed. Further 
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characterization of the Gag-PI(4,5)P2 interaction using the liposome-binding assay 




















Fig. 2.1. Overexpression of 5ptaseIV relocalizes Gag from the PM to perinuclear 
compartments and cytosol 
HeLa cells expressing GagVenus (A and B) or GagmRFP (B) along with full-length 
5ptaseIV  (FL) or the 1 derivative ( 1) were immunostained with anti-Myc (for 
5ptaseIV) and analyzed by a Nikon TE2000 microscope. The number of cells with 1) 
Gag localized at the PM (small arrows/grey); 2) Gag localized predominantly at 
intracellular compartments (arrow heads/white); and 3) Gag localized only in the cytosol 
(large arrows/black), were counted. At least 100 5ptaseIV-positive, Gag-positive cells 
were examined for each condition.  In C, lysates of HeLa cells transfected with pNL4-
3/PR
-
, pNL4-3/GagVenus, or pNL4-3/GagmRFP, were subjected to SDS-PAGE and 
analyzed by immunoblotting using HIV-Ig, anti-GFP, or anti-DsRed.  Note that 
predominantly single bands were detected using antibodies against fluorescent proteins. 
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Fig. 2.2. Membrane binding of WT Gag is reduced in 5ptaseIV-overexpressing cells 
HeLa cells expressing WT or Fyn(10)fullMA Gag along with full-length 5ptaseIV (FL) 
or the 1 mutant were pulse-labeled for 5 min and chased for 20min. Post-nuclear 
supernatants of cell homogenates were subjected to membrane flotation centrifugation. 
A) Membrane (M)- and non-membrane (NM)-bound Gag was recovered by 
immunoprecipitation and subjected to SDS-PAGE. B) The labeled Gag protein was 
quantified by phosphorimager analysis and the membrane binding efficiency was 
calculated. Data from six (WT) or four [Fyn(10)fullMA] different experiments are shown 
as means ± standard deviation. p values were determined using Student’s t-test. (ns=not 
significant, ** p<0.005)  
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Fig. 2.3. Gag binds PI(4,5)P2 in a concentration-dependent manner  
[
35
S]-labeled WT Gag was synthesized in the in vitro transcription and translation system 
by using reticulocyte lysates and was incubated with PC:PS (2:1) liposomes containing 
varying amounts of PI(4,5)P2. The reactions were subjected to membrane flotation 
centrifugation, and five 1-ml fractions were collected from each tube. M, liposome-
bound; NM, non-liposome-bound.  Fractions were subjected to SDS-PAGE followed by 
autoradiography (A).  The amount of labeled Gag in each fraction was quantified using a 
phosphorimager and the percentage of labeled Gag in the membrane-bound fraction 
versus total amount of labeled Gag was calculated (B).  For B, data from seven (0 and 
7.25 mol%), five (0.63 mol%) and four (2.1, 3.52, and 5.71 mol%) different experiments 
are shown as means ± standard deviation. p values were determined between 0% 
PI(4,5)P2 and various percentages of PI(4,5)P2 using Student’s t-test (ns=not significant, 














S]-labeled WT Gag was synthesized in the in vitro transcription and translation system 
by using reticulocyte lysates and was incubated with liposomes containing varying 
amounts of acidic phospholipids. In A and B, liposomes containing increased levels of PS 
were compared with liposomes containing 62.75 mol% PC, 30 mol% PS, and 7.25 mol% 
PI(4,5)P2.  In C and D, 7.25 mol% of PI(4,5)P2, PI(3,5)P2, and PI(3,4,5)P3 were compared 
in the context of the PC:PS (2:1) liposomes.  The fractions were collected and analyzed 
as in Fig. 2.4. M, liposome-bound; NM, non-liposome-bound. For B and D, data from 














Fig. 2.5. Myristoylation-defective mutant Gag does not bind liposomes efficiently 
even in the presence of a high percentage of PI(4,5)P2 





H]-myristic acid.  The major band (labeled Pr55
Gag
) 
comigrated with Gag immunoprecipitated from lysates of HeLa cells transfected with 
pNL4-3/PR
-
 in a parallel experiment (data not shown).  In addition to the Pr55
Gag
 band, 
three minor bands (asterisk) were detected in the in vitro translation reaction of WT Gag 
performed in the presence of the [
35
S]-labeled amino acids.  Two of the minor bands that 
are also labeled with 
3
H likely represent Gag species arising from premature termination 
of translation, whereas the one band labeled only with 
35
S may be formed by internal 
ribosomal entry.  In vitro translation reactions for 1GA Gag as well as other Gag 
derivatives used in this study (data not shown) contained the same minor bands with 
similarly low abundance. B) [
35
S]-labeled WT Gag or myristoylation mutant (1GA) Gag 
was synthesized as in Fig 2.3 and incubated with liposomes containing or not containing 
PI(4,5)P2. The reactions were subjected to membrane flotation centrifugation and 
fractions were analyzed as in Fig. 2.3. The relative liposome binding efficiency for each 
condition was calculated after setting the binding efficiency of WT Gag with PI(4,5)P2-
containing liposomes to 100%. Data from three different experiments are shown as 








Fig. 2.6.  Addition of an efficient membrane binding sequence does not eliminate the 
requirement for PI(4,5)P2 in Gag-liposome binding. 
A) Schematic representation of Gag derivatives with the Fyn N-terminal sequence. 
Myristoylation (m) and palmitoylation (palm) sites are shown. B) [
35
S]-labeled WT Gag, 
Fyn(10)fullMA Gag, and Fyn(10) MA Gag, were synthesized  and incubated with 
liposomes as in Fig. 2.4. The reactions were subjected to membrane flotation 
centrifugation and the fractions were analyzed as in Fig. 2.3. C) The amount of labeled 
Gag in each fraction was quantified using a phosphorimager, and statistical analysis was 
performed as in Fig. 2.4. Data from four different experiments are shown as means ± 
standard deviation. p values were determined using Student’s t-test (***p<0.001, * 
p<0.05, ns= not significant). 
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Fig. 2.7. PM localization of Fyn(10)fullMA Gag is still sensitive to PI(4,5)P2 
depletion in cells 
A) HeLa cells expressing WT, Fyn(10)fullMA, or Fyn(10) MA GagVenus along with 
full-length 5ptaseIV (FL) or the 1 mutant ( 1) were immunostained with anti-Myc 
antibody and analyzed with a Nikon TE2000 microscope.  B) The number of cells with 1) 
Gag localized at the PM (small arrows/grey); 2) Gag localized predominantly at 
intracellular compartments (arrow heads/white); and 3) Gag localized only in the cytosol 
(large arrows/black), were counted as in Fig. 2.1. Note that, for cells expressing 
Fyn(10) MA Gag, a majority of cells showing Gag signals at the intracellular vesicles 




Fig. 2.8. Virus release of Fyn(10)fullMA Gag is still sensitive to PI(4,5)P2 depletion 
in cells 
A) HeLa cells expressing WT, Fyn(10)fullMA, or Fyn(10) MA Gag, along with full-
length 5ptaseIV (FL) or 1 mutant ( 1)  were metabolically labeled for 120 min. Cell- 
and virus-associated Gag were recovered by immunoprecipitation and analyzed by SDS-
PAGE.  B) Signal intensity of labeled Gag was quantified by phosphorimager analysis. 
Virus release efficiency was calculated as the amount of virus-associated Gag as a 
fraction of total Gag synthesized during the labeling period and normalized to the virus 
release efficiency in 5ptaseIV 1 expressing cultures. The average virus release 
efficiencies by cells expressing WT, Fyn(10)fullMA, and Fyn(10) MA Gag along with 
5ptaseIV 1 are 15.6%, 27%, and 21.3%, respectively. Data from four different 
experiments are shown as means ± standard deviation. p values were determined using 















S]-labeled WT Gag and basic domain mutants (29KE/31KE or 29KT/31KT) were 
synthesized and incubated with liposomes as in Fig. 2.5.  A) The reactions were subjected 
to membrane flotation centrifugation and the fractions were analyzed as in Fig. 2.3. B) 
The amount of labeled Gag in each fraction was quantified using a phosphorimager and 
the statistical analysis was performed as in Fig. 2.5. Data from three different 
experiments are shown as means ± standard deviation. p values were determined using 
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Opposing mechanisms involving RNA and lipids regulate HIV-1 Gag membrane 
binding through the highly basic region of the matrix domain 
 
ABSTRACT 
Membrane binding of Gag, a crucial step in HIV-1 assembly, is facilitated by 
bipartite signals within the matrix (MA) domain: N-terminal myristoyl moiety and the 
highly basic region (HBR). The data from chapter II has shown that Gag interacts with a 
plasma-membrane-specific acidic phospholipid, phosphatidylinositol-(4,5)-bisphosphate 
[PI(4,5)P2], via the HBR, and that this interaction is important for efficient membrane 
binding and plasma membrane targeting of Gag.  Generally, in protein-PI(4,5)P2 
interactions, basic residues promote the interaction as docking sites for the acidic 
headgroup of the lipid.   In this study, toward better understanding of the Gag-PI(4,5)P2 
interaction, we sought to determine the roles played by all the basic residues in the HBR.  
We identified three basic residues promoting PI(4,5)P2-dependent Gag-membrane 
binding.  Unexpectedly, two other HBR residues, Lys25 and Lys26, suppress membrane 
binding in the absence of PI(4,5)P2 and prevent promiscuous intracellular localization of 
Gag.  This inhibition of non-specific membrane binding is likely through suppression of 
myristate-dependent hydrophobic interaction since mutating Lys25 and Lys26 enhances 
 80
binding of Gag with neutral-charged liposomes.  These residues were previously reported 
to bind RNA.  Importantly, we found that RNA also negatively regulates Gag membrane 
binding.  In the absence but not presence of PI(4,5)P2, RNA bound to MA HBR abolishes 
Gag-liposome binding. Altogether, these data indicate that the HBR is unique among 
basic phosphoinositide-binding domains, as it integrates three regulatory components, 




HIV-1 assembly is a multi-step process mediated primarily by the viral structural 
protein, Gag. This protein, synthesized as a polyprotein precursor, Pr55
Gag
, contains four 
major domains: matrix (MA), capsid (CA), nucleocapsid (NC) and p6. CA and NC 
contain determinants for Gag multimerization, whereas p6 facilitates release of virus 
particles [1, 2]. In most cell types, Gag assembles on the cytoplasmic leaflet of the 
plasma membrane (PM). MA is required for this PM-specific targeting as well as the 
lipid bilayer binding of Gag. 
MA has bipartite entities that facilitate membrane binding of Gag: (i) the N-
terminal myristoyl moiety; and, (ii) a highly basic region (HBR) comprising of residues 
17 to 31[3-5]. The N-terminal myristate is normally sequestered within the globular head 
domain of MA[6], which also includes the HBR. A structural change, either through Gag 
multimerization or phosphatidylinositol-(4,5)-bisphosphate [PI(4,5)P2] binding to MA, is 
required to expose the myristate and enhance membrane binding[6, 7].  This mechanism 
is known as the myristoyl switch[8, 9].  Structural and biochemical studies suggest that 
 81
the HBR of HIV-1 MA and analogous regions of other retroviral MA are apposed to face 
the cytoplasmic leaflet of membranes and facilitate membrane binding by interacting 
with acidic lipids [4, 10-14].  In addition, MA, especially the HBR, has been shown to 
interact with RNA [15-19] although the role of this interaction in virus assembly is less 
well understood.  The HBR is also implicated in other steps of virus replication such as 
the postentry process (for review, see [20]). 
 Many cellular proteins that interact peripherally with the cytoplasmic leaflet of 
membranes have basic amino acid-rich domains [21]. The subcellular localization of 
these proteins generally depends on the specific binding of their basic domains with 
acidic lipids of target membranes. For example, the pleckstrin homology domain of 
phospholipase C 1(PHPLC 1) has basic residues located on the surface of a binding 
pocket for PI(4,5)P2, a PM-specific acidic lipid. These basic residues specifically interact 
with the phosphates on the inositol headgroup of PI(4,5)P2[22]. This interaction allows 
PHPLC 1 to localize to the PM. Similarly, basic residues of other phosphoinositide-binding 
domains play crucial roles in specific interactions with target membranes. 
Previously, we showed that depleting cellular PI(4,5)P2 reduces virus release of 
HIV-1 significantly and relocalizes Gag from the PM to cytosol or intracellular 
compartments [23, 24]. Not only HIV-1, but other retroviruses such as HIV-2, murine 
leukemia virus, and Mason-Pfizer monkey virus also require PI(4,5)P2 or other 
phosphoinositides for efficient virus release [25-28]. Several studies using various in 
vitro techniques, including NMR, protein foot printing, liposome binding, and monolayer 
membrane binding suggest that MA interacts specifically with PI(4,5)P2[7, 24, 29, 30]. A 
recent lipid analysis study demonstrated that PI(4,5)P2 is enriched in the HIV envelope in 
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an MA-dependent manner, confirming the MA-PI(4,5)P2 interaction in vivo [26]. These 
studies suggest that MA basic residues, in particular those in the HBR, promote PI(4,5)P2 
interaction and membrane binding, as observed for basic residues in other 
phosphoinositide-binding domains. However, the contribution of each basic residue in the 
HBR to the interaction between full-length Gag and PI(4,5)P2-containing membrane 
remains to be examined. 
Previous reports showed that mutating lysines 29 and 31 to threonines 
(29KT/31KT) within the HBR relocalizes Gag from the PM to intracellular 
compartments, as observed for wild-type (WT) Gag in PI(4,5)P2-depleted cells[31]. 
Consistent with the altered localization, the in vitro liposome binding assay showed that 
29KT/31KT Gag binds PI(4,5)P2 less efficiently compared to WT Gag[24]. However, the 
Gag-PI(4,5)P2 interaction was not completely abolished, suggesting a role for other basic 
amino acids in this interaction.   
In this study, towards better understanding of the Gag-PI(4,5)P2 interaction, we 
sought to identify all the basic residues in the HBR important for this interaction. We 
confirmed that the HBR as a whole is indeed essential for PI(4,5)P2 interaction and 
efficient membrane binding of Gag. Surprisingly, analysis of a panel of Gag mutants 
revealed that a part of the HBR actually suppresses membrane binding in the absence of 
PI(4,5)P2.  This suppression is likely due to inhibition of the myristate-dependent 
hydrophobic interaction. Furthermore, RNA bound to the HBR also inhibits Gag-
membrane binding through inhibition of acidic lipid binding and to a lesser extent via 
suppression of myristate exposure. Altogether, these results showed that the HBR 
regulates membrane binding in both positive and negative manners.  Data presented in 
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this chapter suggest a novel, RNA-dependent mechanism by which HIV-1 Gag ensures 
specific binding to the PI(4,5)P2-containing membrane, i.e., the PM.  To our knowledge, 
this is the first example of a protein-phospholipid interaction directly suppressed by 
RNA. 
 
 MATERIALS AND METHODS 
Cells and Plasmids 
HeLa cells were cultured and maintained in DMEM supplemented with 5% fetal bovine 
serum. HIV-1 molecular clone pNL4-3[32], its derivative encoding YFP-tagged Gag 
(pNL4-3/GagVenus) and a Gag expression vector for in vitro translation reaction, 
pGEMNLNR, were previously described[24]. pNL4-3/1GA, pNL4-3/25KT/26KT, 
pNL4-3/17KT/19RL, pNL4-3/29KT/31KT, pNL4-3/19RL, pNL4-3/21RL were kind gifts 
from E. Freed [33, 34]. Other MA changes were introduced into pNL4-3 by PCR 
mutagenesis. MA changes in pNL4-3 derivatives were also introduced into pGEMNLNR 
and pNL4-3/GagVenus using standard molecular biology techniques. 
pGEMNLNR/delNC was constructed by replacing BssHII to PflMI fragment (nt 711-
5297) with that of pNL4-3/delNC (a kind gift from D. Ott)[35].  
Liposome binding assay 
Liposome binding assay was performed as previously described [24]. Briefly, 
radiolabeled Gag is synthesized using in vitro transcription and translation coupled 
reaction mix containing rabbit reticulocyte lysates (Promega). Liposomes containing 
corresponding lipids were added after 30 minutes at 30°C and incubated further for 90 
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minutes. Then, the liposome-bound and non-liposome-bound Gag were separated by 
equilibrium flotation centrifugation. 
For RNase treatment experiments, the above protocol was modified as following. Gag 
synthesis was performed at 30°C for 90 minutes. Subsequently, 1 μl of RNase, which is a 
mixture of pyrimidine-specific endoribonucleases from bovine pancreas (Cat. No: 
11119915001, Roche Applied Science), was added to 25 μl of the reaction mix and 
incubated for 20 minutes at 37ºC. Liposomes were then added and incubated for 15 
minutes at 30ºC before equilibrium flotation centrifugation was performed.  
The top two fractions were considered liposome-bound and the bottom three as non-
liposome-bound Gag. The liposome binding efficiency was calculated as the amount of 
liposome-bound Gag as a fraction of total Gag. 
Virus release assay and statistical analysis 
Virus release assay was performed as previously described[23].  Statistical analysis was 
performed as previously described[23]. 
Quantification of RNA bound to Gag in rabbit reticulocyte lysate 
The protocol described by Peritz et al was adapted for purifying RNA bound to Gag[36]. 
Briefly, rabbit reticulocyte lysate containing S-35 labeled Gag was diluted with lysis 
buffer [100mM KCl, 5mM MgCl2, 10mM HEPES, 0.5% NP-40, 1mM DTT, 100U/ml 
rRNasin (Promega) and 1 tablet/50ml Complete protease inhibitor cocktail (Roche)] and 
precleared at 4 degrees for 1 hour with protein A sepharose beads. The precleared lysate 
was incubated with HIV-Ig - protein A complex at 4 degrees overnight. The 
immunoprecipitated complex was washed four times with lysis buffer, resuspended in 
lysis buffer containing 0.1% SDS and proteinase K (0.3mg/ml) and incubated at 50 
 85
degrees for 30 minutes. The supernatant was mixed with ethanol and added to Qiagen 
RNasy column, washed and eluted as described by the manufacturer. The RNA was then 
quantified using Invitrogen Quant-iT Ribogreen RNA reagent as per the manufacturer’s 
protocol. The amount of RNA was normalized to the levels of radioactive Gag 
immunoprecipitated and the RNA bound to WT Gag was set to 100 percent. 
 
RESULTS 
The HBR of the MA domain is essential for PI(4,5)P2-dependent membrane binding 
of Gag 
To examine whether the HBR of MA is indeed important for Gag-PI(4,5)P2 
interaction, we mutated all the positively charged residues (6A2T) within the HBR(Fig. 
3.1). This mutant was then analyzed for PI(4,5)P2-dependent membrane binding by 
previously described in vitro liposome binding assay[24]. In this assay, myristoylated 
full-length Gag is synthesized using rabbit reticulocyte lysates and incubated with 
liposomes. Liposome-bound and non-liposome-bound Gag proteins are separated by 
sucrose gradient membrane flotation centrifugation. As shown in Fig. 3.2, compared to 
WT Gag, binding of 6A2T Gag to PI(4,5)P2-containing liposomes was significantly 
reduced. To examine the effect of the 6A2T change on the localization of Gag in cells, 
we introduced the same mutations in a Gag derivative tagged with Venus, a variant of 
yellow fluorescent protein (GagVenus) [24, 37]. Consistent with the weak liposome 
binding, 6A2T GagVenus showed a hazy, cytosolic signal in most cells. Additionally, 
perinuclear localization of GagVenus was observed in some cells (Fig. 3.3). This is in 
contrast to WT GagVenus that localizes predominantly on the PM. The virus release was 
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undetectable for the 6A2T mutant. Altogether, these results suggest that the HBR likely 
forms a binding site for PI(4,5)P2 and that this interaction is important for efficient Gag 
membrane binding and virus release.  
MA basic residues Lys25 and Lys26 in the HBR suppress PI(4,5)P2-independent 
membrane binding and inhibit promiscuous localization of Gag 
To pinpoint the residues essential for Gag-PI(4,5)P2 interaction, we analyzed 
liposome binding of Gag mutants with single or double amino acid substitutions of the 
basic residues in the MA HBR by using in vitro liposome binding assay (Fig. 3.1 and 
Fig.3.2). Several of these mutants have been previously studied with respect to other 
proposed MA functions [19, 20, 33, 34]. Overall, the mutants could be categorized into 
three different phenotypes: (i) reduced PI(4,5)P2 binding [17KT, 17KT/29KT, and 
29KT/31KT], (ii) increased PI(4,5)P2-independent binding [25KT/26KT], and (iii) no 
change compared to WT [all of the other mutants].  Altogether, these experiments 
suggest that MA basic residues 17, 29, and 31 promote MA-PI(4,5)P2 interaction. 
Among the Gag mutants examined, the 25KT/26KT mutant, where lysines 25 and 
26 were changed to threonines, showed no significant change in binding to PI(4,5)P2-
containing liposomes. Unexpectedly, however, this mutant had significantly elevated 
binding to control liposomes that lack PI(4,5)P2(Fig. 3.2). These results suggest that, in 
addition to facilitating membrane binding through PI(4,5)P2 interaction, some basic 
residues in the HBR inhibit PI(4,5)P2-independent membrane binding.  
To characterize the 25KT/26KT mutant Gag further, we analyzed both virus 
release and localization using cell-based assays as described previously[24]. Consistent 
with the lack of requirement for PI(4,5)P2 observed in the in vitro liposome binding assay 
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(Fig. 3.2), the virus release efficiency of 25KT/26KT was substantially augmented 
compared to WT (Fig. 3.3B).  Notably, 25KT/26KT GagVenus displayed promiscuous 
membrane binding in cells, localizing both at the PM and intracellular compartments 
(Fig. 3.3A). This promiscuous localization of Gag is not due to protein aggregation as 
intact virus particles bud from both PM and intracellular compartments for this 
25KT/26KT mutant (Fig. 3.4). Altogether, these results indicate that MA basic residues 
25 and 26 inhibit PI(4,5)P2-independent membrane binding of Gag. 
RNA inhibits liposome binding of Gag 
Previous studies showed that the residues Lys25 and Lys26 can interact with 
RNA[17-19]. Therefore, it is conceivable that the 25KT/26KT mutations abolish RNA 
binding and allow other MA basic residues to freely interact with acidic lipids thereby 
enhancing promiscuous membrane binding. To examine whether RNA does interfere 
with Gag membrane binding, we first tested the effect of RNase treatment on the 
liposome binding of WT Gag. Remarkably, treating WT Gag with RNase before 
incubation with liposomes greatly enhanced interaction of Gag with control liposomes 
containing phosphatidylcholine (PC) and phosphatidylserine (PS) [PC+PS] (Fig. 3.5).  A 
similar increase was observed with PI(4,5)P2-containing liposomes [PC+PS+PI(4,5)P2].  
Notably, however, as we reported previously[24], a substantial amount of Gag was bound 
to PI(4,5)P2-containing liposomes even without RNase treatment (Fig.3.5). These results 
indicate that Gag-membrane binding is suppressed almost completely by RNA unless 
PI(4,5)P2 is present. 
To determine if the phenotype of 25KT/26KT Gag can be explained by the loss of 
RNA binding, we examined the effect of RNase treatment on liposome binding of this 
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mutant Gag. The enhancement of membrane binding by RNase treatment was smaller 
than that observed for WT, especially in the absence of PI(4,5)P2 (Fig. 3.5). These data 
suggest that the 25KT/26KT mutation and RNase treatment enhance membrane binding 
by overlapping mechanisms.  
The 25KT/26KT changes increase the hydrophobic interaction with membranes 
Efficient membrane binding of Gag requires both the myristoyl moiety and the 
HBR. It is still possible that the 25KT/26KT mutant enhances membrane binding by 
constitutively exposing the myristoyl moiety. To test this hypothesis, we analyzed the 
binding of 25KT/26KT Gag to liposomes containing PC alone. Because PC is a neutral 
lipid, binding of Gag to these liposomes would likely be mediated by hydrophobic 
interaction through N-terminal myristate moiety. Consistent with the previous findings 
that the myristate moiety is sequestered inside the globular head of MA, and that 
PI(4,5)P2 binding is required for facilitating myristate exposure [2, 6, 7], WT Gag was 
unable to bind well to PC liposomes (Fig.3.6). However, the double mutant 25KT/26KT 
was able to bind efficiently to liposomes containing only PC (Fig. 3.6). This increased 
membrane binding of 25KT/26KT was myristate dependent as it was completely 
abolished when myristoylation signal was mutated on Gag (data not shown). These 
results suggest that the 25KT/26KT mutant readily exposes the myristate.  Therefore, it is 
likely that lysines 25 and 26 suppress non-specific membrane binding by regulating 
hydrophobic interactions dependent on the myristate. 
RNA bound to MA but not NC inhibits liposome binding of Gag  
As described above, RNase treatment enhanced membrane binding of both WT 
and to a lesser extent 25KT/26KT Gag (Fig. 3.5). As RNA-mediated inhibition of 
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membrane binding may represent a unique mode of regulation in virus assembly, we 
sought to understand the mechanism of this inhibition. Coimmunoprecipitation 
experiments showed that both MA HBR and NC facilitate RNA binding to Gag in 
reticulocyte lysates (Fig. 3.7). To test if RNA bound to NC is involved in the inhibition of 
membrane binding, we analyzed NC-deleted Gag (delNC) for RNase sensitivity. 
Liposome binding of delNC Gag was increased upon RNase treatment to a similar extent 
as WT Gag (Fig 3.8). These results suggest that at least in the liposome binding assay, 
NC is not required for RNA-mediated inhibition of membrane binding of Gag.  
RNase treatment increases both the interaction of MA basic residues with acidic 
lipids and the myristate-dependent hydrophobic interaction  
The results presented above are consistent with the possibility that RNA bound to 
MA HBR blocks the interaction of the HBR basic residues with acidic lipids and 
interferes with Gag membrane binding. However, it is also conceivable that RNA binding 
to the HBR might reduce myristate exposure thereby suppressing membrane binding of 
Gag. Both of these possibilities are consistent with the observation that membrane 
binding of 25KT/26KT Gag that has readily exposed myristate (Fig. 3.6) is enhanced 
upon RNase treatment markedly but not as much as WT Gag (Fig. 3. 5). Hence, to further 
understand the mechanism by which RNA inhibits membrane binding, we analyzed the 
myristoylation-defective Gag mutant (1GA). Interestingly, although RNase treatment did 
increase membrane binding of 1GA Gag, the extent of increase depended on the 
composition of liposomes used in the assay. 1GA Gag bound PI(4,5)P2-containing 
liposomes as efficiently as WT Gag upon RNase treatment (Fig. 3.9A). This strongly 
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supports the model that interaction of basic residues in the HBR with acidic lipids is 
increased upon RNase treatment. 
In contrast, RNase treatment increased binding of 1GA Gag to PC+PS liposomes 
only modestly compared to that of WT Gag. These results are consistent with the 
possibility that RNA also inhibits membrane binding partially by sequestration of 
myristate. Indeed, WT Gag did show a modest increase in PC-liposome binding upon 
RNase treatment, whereas 1GA Gag showed no increase (Fig. 3.9B). These data suggest 
that removal of RNA has an impact on the myristoyl switch as well. Altogether, these 
results indicate that RNA inhibits membrane binding both by preventing the electrostatic 
interaction between basic residues and acidic lipids and by suppressing the myristate-
dependent hydrophobic interaction. 
 
DISCUSSION 
Phosphoinositide-binding domains found in cellular proteins contain basic 
residues that are essential for interaction with acidic headgroups of phosphoinositides 
[21]. Similarly, the current study showed that some basic residues within the HBR 
(Lys17, Lys29, and Lys31) are important for efficient Gag membrane binding mediated 
by PI(4,5)P2 (Fig. 3.2). However, our study also revealed that the HBR contains basic 
residues (Lys25 and Lys26) that suppress membrane binding of Gag (Fig 3.2).  This 
negative regulation of membrane binding by Lys25 and Lys26 likely occurs via myristate 
sequestration (Fig. 3.6). Consistent with the increased PI(4,5)P2-independent liposome 
binding, 25KT/26KT Gag localizes promiscuously in cells and releases virus particles 
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more efficiently than WT Gag (Fig. 3.3,3.4), a phenotype reminiscent of Gag derivatives 
with MA globular head deletions[38].   
This work also identified RNA as a negative regulator of Gag membrane binding. 
Several in vitro studies showed that HIV-1 MA interacts with RNA via its HBR[17-19]. 
Therefore, competition between RNA and acidic lipids for binding to the HBR at least 
partly accounts for the RNA-mediated suppression of Gag membrane binding. Consistent 
with this hypothesis, in other in vitro experiments performed in the absence of RNA, 
binding of MA to PS has been readily observed [39-41], whereas in our system, Gag 
binding to the PC+PS liposomes was negligible without RNase treatment.  Importantly, 
in contrast to PC+PS liposomes, substantial amount of Gag binds to PC+PS+PI(4,5)P2 
liposomes even without RNase treatment (Figs 3.5 and 3.9). Consistent with these data, 
Eric Barklis’ group reported that PI(4,5)P2-containing liposomes out-compete 
oligonucleotides for binding to beads coated with purified myristylated MA domain [42].  
Thus, it is likely that PI(4,5)P2, but not other acidic lipids such as PS, can bind the HBR 
in the presence of RNA. In addition, exposure of myristate may also be more dependent 
on PI(4,5)P2 binding in the presence of RNA, because RNA binding to MA HBR also 
reduces myristate-dependent hydrophobic interaction (Fig. 3.9). In any case, our data 
suggest that RNA binding to MA represents a novel regulatory mechanism in Gag 
membrane binding. 
It remains to be determined whether RNA bound to the HBR inhibits unregulated 
membrane binding in cells.  In our in vitro system, the RNA concentration is estimated to 
be lower than that in the cytoplasm of HeLa cells. Nonetheless, the inhibition of 
membrane binding by RNA does not require NC, the major RNA binding domain (Fig. 
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3.8). However, in cells, it is likely that the viral genomic RNA bound to NC also binds 
MA because of their close proximity.  This model is also consistent with a recently 
proposed folded-over conformation of Gag [43, 44] (not depicted in Fig. 3.10). Notably, 
two recent reports suggest that RNA export from the nucleus plays a key role in MA-
mediated membrane binding of Gag [45, 46]. These authors observed that HIV Gag 
assembly defects linked to specific Gag mRNA export pathways could be rescued by 
increasing membrane binding ability of Gag, either by MA mutations or replacing MA 
with heterologous membrane binding domains [45, 46]. In light of the results presented 
here, it is possible that nuclear export pathways used by viral RNAs affect MA-RNA 
interactions, which in turn, influence Gag membrane binding.  This hypothesis is also in 
agreement with the observed autoinhibition of Gag membrane binding by HIV-1 MA in 
murine cells [47, 48]. 
It has been long known that retroviral MA interacts with RNA[15-19, 49-53]. 
Although genomic RNA encapsidation does not require MA in the case of HIV-1 [54], a 
variety of roles have been suggested for the retroviral MA-RNA interaction in the later 
half of the virus life cycle. These include (i) regulation of viral mRNA translation [18, 
55], (ii) encapsidation of genomic viral RNA [56], (iii) dimerization of encapsidated 
RNA[57, 58], and (iv) enhancement of Gag assembly[59, 60]. Thus, it is tempting to 
speculate that binding of the HBR to both PI(4,5)P2 and RNA may play a key role in 
coordinating the four-way interactions between the PM, viral RNA, MA, and NC during 
the late phase of the retrovirus life cycle.  For example, once Gag reaches the PM, the 
viral RNA bound to MA might get displaced by the HBR-PI(4,5)P2 interaction. This 
displaced RNA may then act as a scaffold for NC-dependent Gag multimerization and 
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facilitate efficient particle assembly at the PM. Such a process might also require cellular 
proteins reported to play a role in Gag multimerization or RNA packaging, including 
ATP-binding cassette protein in the E subfamily (ABCE1)[61, 62] and Staufen-1[63]. 
Clearly, further studies are necessary for addressing interrelationships between events 
during the late phase.  
In summary, our data indicate that the HBR within MA modulates membrane 
binding in three different ways: positively by interaction with PI(4,5)P2, and negatively 
by suppression of myristate-dependent hydrophobic interaction and by interaction with 
RNA.  RNA binding to MA HBR not only interferes with interactions between MA basic 
amino acids and acidic lipids, but also appears to reduce myristate exposure.  Based on 
this and previous studies, we put forth the following model (Fig. 3.10). Both RNA 
binding and suppression of myristate exposure mediated by the HBR prevent Gag from 
premature or non-specific membrane binding. Once Gag reaches PI(4,5)P2-containing 
membranes such as the PM, PI(4,5)P2 binds the HBR, which then triggers myristate 
exposure and stabilizes binding to the lipid bilayer. However, if myristate sequestration is 
blocked (e.g., by the 25KT/26KT mutations) or if RNA detaches from the HBR (e.g., by 
RNase treatment), Gag binds membrane in a non-specific, PI(4,5)P2-independent manner 
(Fig. 3.10). Co-operation of interactions with multiple membrane factors, which enhances 
the robustness and specificity of membrane binding, is prevalent in phosphoinositide-
binding domains [21]. However, MA HBR is unique among these domains for integrating 
opposing regulatory mechanisms to ensure specificity for the target membrane that 
contains PI(4,5)P2.  
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Fig. 3.1. Amino acid mutations in the MA HBR analyzed in this study 
The wild type NL4-3 sequence is shown using single-letter amino acid code. The name of 
the mutant and the changes in the amino acid sequence are shown. Dashes represent 





Fig. 3.2. Lys25 and Lys26 in the HBR inhibit membrane binding of Gag  
 [
35
S]-labeled WT Gag and Gag mutants with indicated amino acid substitutions were 
synthesized by the in vitro transcription and translation system using reticulocyte lysates 
and incubated with liposomes containing or not containing PI(4,5)P2.  The reactions were 
subjected to membrane flotation centrifugation and five 1-ml fractions were collected 
from each tube. Representative gels are shown in the top panel.  M, liposome-bound; 
NM, non-liposome-bound.  The relative liposome binding efficiency was calculated in 
comparison to the binding efficiency of WT Gag with PI(4,5)P2-containing liposomes for 
each experiment. Data from three independent experiments are shown as means ± 
standard deviation. p values were determined using Student’s t-test as a comparison to 












Fig.3.3 Mutations in Lys25 and Lys26 show promiscuous localization and enhanced 
virus release 
A) HeLa cells expressing WT, 6A2T and 25KT/26KT GagVenus were analyzed using 
Nikon TE2000 microscope. B) HeLa cells expressing HIV molecular clones encoding 
WT or 25KT/26KT Gag were metabolically labeled for 2 h. Cell- and virus-associated 
Gag were recovered by immunoprecipitation. Virus release efficiency was calculated as 
the amount of virus-associated Gag as a fraction of total Gag synthesized during the 
labeling period and normalized to the virus release efficiency of WT.  The average virus 
release efficiencies for WT and 25KT/26KT are 7.22% and 17.85%, respectively.  Data 































Fig.3.4 25KT/26KT mutant forms virus particles both at PM and intracellular 
compartments 
HeLa cells were transfected with HIV molecular clone encoding 25KT/26KT Gag. 16 
hours post-transfection, they were fixed and analyzed by transmission electron 
microscopy. Note that the virus particles form both at PM (black arrows) and intracellular 
compartments consistent with the localization of GagVenus in Fig. 3.3. 
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Fig.3.5. RNA inhibits membrane binding of Gag  
WT and 25KT/26KT Gag were synthesized using rabbit reticulocyte lysates and either 
treated or not treated with RNase. Subsequently, liposomes containing indicated lipids 
were added, and the liposome binding efficiency was calculated as described in Materials 
and Methods. M, liposome-bound; NM, non-liposome-bound. Data from three (PC+PS) 
or four (PC+PS+PI(4,5)P2) independent experiments are shown as means ± standard 
deviation.  ns=not significant,** p<0.01, *** p<0.001. There is a statistically significant 
difference (*) in binding to PI(4,5)P2-containing liposomes between RNase-treated WT 










Fig.3.6. 25KT/26KT Gag binds efficiently to liposomes lacking acidic phospholipids 
Binding of WT and 25KT/26KT Gag to liposomes containing indicated lipids were 
analyzed as in Fig. 3.2. Data from three independent experiments are shown as means ± 
standard deviation.  ns=not significant,*p<0.05. There are no statistically significant 






















Fig. 3.7. Relative percentage of RNA bound to Gag in rabbit reticulocyte lysate 
WT, delNC, 6A2T, 6A2TdelNC Gag were synthesized using rabbit reticulocyte lysate 
and either treated or not treated with RNase. Subsequently, Gag was immunoprecipitated 
and the amount of RNA coimmunoprecipitated was quantified as described in Materials 
and Methods. Relative percentage of RNA bound to Gag derivatives is shown after 
setting WT without RNase treatment as 100 percent. Data from three independent 



















Fig.3.8. Nucleocapsid is not required for RNA-mediated inhibition of Gag-
membrane binding 
 Liposome binding of WT and delNC Gag was analyzed as in Fig.3.5. using PC+PS 
liposomes. Data from three independent experiments are shown as means ± standard 
deviation. ** p<0.01. There is no statistically significant difference in membrane binding 









Fig.3.9. MA-bound RNA suppresses membrane binding of Gag by inhibiting 
interactions between basic residues and acidic lipids and by reducing the myristate-
dependent interaction 
A. and B. Liposome binding of WT and 1GA Gag was analyzed as in Fig. 3.5 using 
liposomes containing either PC+PS or PC+PS+PI(4,5)P2 (A) or only PC (B). Data from 
three to five independent experiments are shown as means ± standard deviation. ns=not 
significant,* p<0.05,** p<0.01,*** p<0.001. There is a statistically significant difference 
(*) in binding to PC+PS liposomes but not PI(4,5)P2-containing liposomes between WT 




Fig.3.10.  A model for the regulation of Gag-membrane binding specificity  
PI(4,5)P2-dependent and independent membrane binding of WT, 25KT/26KT and 
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HIV particle production is a multi-step process that occurs specifically on the 
plasma membrane (PM) or in compartments that are continuous with the PM. How Gag 
directs this assembly process to the PM has been the focus of my thesis and this chapter 
will discuss the results from Chapter II and III and some of the future directions for the 
project. The first part of the discussion focuses on the data related to the role of PI(4,5)P2 
in HIV-1 assembly and how the data might be expanded to a broader range of 
physiologically relevant cell types. In addition, I will also discuss whether the use of 
phosphoinositides in virus assembly is a conserved process among other members of 
Retroviridae family. The second part of the discussion focuses on the role of RNA as a 
negative regulator of membrane binding of Gag. Being a new topic in the field of HIV 
assembly, there are a lot of unanswered questions. Does RNA-mediated inhibition of Gag 
membrane binding occur in cells? What is the identity of the RNA that mediates this 
regulation of membrane binding? Some of these questions will be discussed in light of 
recent preliminary data obtained.  Additionally, I will speculate on how PI(4,5)P2 and 
RNA together may help coordinate steps within the assembly process and the advantages 
associated with this regulation. I will conclude by highlighting how the data obtained in 
this thesis can aid in development of anti-retroviral drugs. 
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Interaction between MA highly basic region and PI(4,5)P2 is important for PM 
targeting and efficient membrane binding of Gag 
Summary of data 
Previous work in the lab has shown that depletion of PI(4,5)P2 in HeLa cells 
relocalizes Gag from the PM to intracellular compartments and significantly reduces 
virus release [1]. Thus, PI(4,5)P2 is an important cellular factor that mediates PM 
association of Gag.  The work in chapter II illustrates, that in addition to relocalizing Gag 
to intracellular compartments, PI(4,5)P2 depletion also increases non-membrane bound 
Gag in HeLa cells. To better understand the role of PI(4,5)P2 in membrane binding of 
Gag, we developed an in vitro liposome-binding assay. Previous studies analyzing Gag-
PI(4,5)P2 interaction used bacterially purified Gag constructs. However, only part of Gag 
can be synthesized in this system due to solubility issues.  In contrast, the in vitro system 
used in this thesis utilizes rabbit reticulocyte lysates that are capable of synthesizing full-
length myristoylated Gag. This multi-domain protein is what mediates assembly in cells. 
Thus, we are analyzing physiologically relevant Gag in our system compared to bacterial 
expression systems. In addition, liposomes are made with defined lipids allowing us to 
specifically analyze the interaction between Gag and lipids of interest. Using this assay, 
we were able to show that Gag interacts with PI(4,5)P2 in a head-group specific manner 
and that this interaction is necessary for efficient liposome binding of Gag (Chapter II).  
Using mutagenesis, we were also able to show that the MA domain of Gag is important 
for this interaction. When the MA domain was removed and an exogenous membrane 
binding signal was added, Gag showed promiscuous localization in cells both in the 
presence or absence of PI(4,5)P2. Interestingly, however, virus release was still reduced 
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when PI(4,5)P2 is depleted, albeit to a lesser extent than WT. These data suggest that 
PI(4,5)P2 may have an additional role in virus assembly and release independent of its 
function as a PM anchor for Gag. Consistent with this hypothesis, a recent study 
suggested that activation of inositol trisphosphate receptor by PI(4,5)P2 hydrolysis and 
subsequent Ca
2+
 mobilization modulate endocytosis of Gag and thus is important for 
virus release [2]. Relationships between this indirect role of PI(4,5)P2 and its role as a 
Gag binding partner remain to be elucidated. 
To further understand the molecular details of Gag- PI(4,5)P2 interaction, we 
tested single and double amino acid substitutions of basic residues within the MA highly 
basic region (HBR) for their ability to bind PI(4,5)P2 using in vitro liposome binding 
assay (Chapter III). Using this assay, we were able to show that lysines at position 17, 29 
and 31 within MA domain are important for efficient Gag-PI(4,5)P2 interaction. 
Surprisingly, mutations of two other lysines at position 25 and 26 increased PI(4,5)P2-
independent membrane binding. Further analysis showed that this mutant is 
promiscuously localized in cells likely due to an exposed myristate. In summary, MA 
HBR has opposing dual role in the context of membrane binding. Some of the basic 
residues directly interact with the acidic lipid PI(4,5)P2 and facilitate efficient membrane 
binding. In contrast, some other basic residues inhibit membrane binding, especially in 
the absence of PI(4,5)P2, by sequestering myristate. Notably, NMR structural analysis 
suggests that when PI(4,5)P2 binds to MA HBR it causes a structural change that induces 
myristate exposure [3]. Thus, PI(4,5)P2 facilitates membrane binding  of Gag not only by 
electrostatic interaction but also by the structural change that can increase the 
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hydrophobic interaction of Gag. Both of these interactions with membrane can 
synergistically enhance and stabilize binding of Gag to the plasma membrane.  
What about the role of PI(4,5)P2 in relevant cell types? 
The work discussed above was mostly performed in HeLa cells. Similar results 
were also obtained using HEK293 and Cos-1 cells [4, 5]. Even though these cells are 
good model cells to study assembly due to the ease of transfection, HIV infects only 
human cells that have CD4 on the surface. Thus, it is important to confirm the role of 
PI(4,5)P2 in these physiologically relevant cell types. 
Recent work from our lab suggests that depletion of PI(4,5)P2 in the natural host 
cells of HIV-1, CD4+ T cells, significantly reduces Gag-membrane association and virus 
release [6]. In addition to T cells, HIV also infects antigen-presenting cells like 
macrophages and dendritic cells. As mentioned in Chapter I, virus assembly occurs in 
sub-cellular compartments called virus-containing compartments (VCC) in these cell-
types [7, 8]. Preliminary work on the role of PI(4,5)P2 in primary macrophages suggests 
that PI(4,5)P2 is necessary for efficient virus release and membrane binding of Gag as 
previously observed in HeLa cells (Fig. 4.1). Thus, PI(4,5)P2 plays an important role in 
virus assembly not only in model cell lines but also in physiologically relevant cell types. 
Does the requirement for PI(4,5)P2 hold true for other types and sub-types of HIV? 
As mentioned in Chapter I, subtype C is the most predominant subtype in the HIV 
pandemic accounting for 50% of the cases. Due to its efficient tissue culture adaptability, 
the subtype studied in the lab is subtype B that accounts for only 10% of the cases. 
Before developing therapeutics against the virus using the data obtained from the lab, it is 
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important to test that the data holds true for all types and strains of HIV. It is also of note 
that although most MA HBR residues are conserved, subtype C has methionine instead of 
lysine at position 29 within MA. This residue has been shown to be important for Gag-
PI(4,5)P2 interaction in HIV-1 subtype B. Lack of a basic residue at position 29 raises the 
possibility that either subtype C does not require PI(4,5)P2 for assembly or that it has a 
different binding site for PI(4,5)P2. Data from my work using a subtype C strain (MJ4) 
suggests that PI(4,5)P2 depletion significantly reduces its virus release efficiency, 
although the defect is less severe (3 fold reduction) compared to the subtype B (7 fold 
reduction) (Fig. 4.2). Further studies are required to pinpoint the residues in subtype C 
that are involved in PI(4,5)P2 interaction. Likewise, NMR study on HIV-2 suggests that 
even though PI(4,5)P2 binds HIV-2 MA, it is unable to efficiently expose myristate as in 
HIV-1. Nevertheless, the virus release of HIV-2 is still significantly reduced upon 
PI(4,5)P2 depletion [9]. Thus, even though there are some type-specific differences, 
overall, the requirement of PI(4,5)P2 for efficient virus release holds true among different 
HIV types and subtypes tested.    
What about other members of Retroviridae family? 
Not only HIV, but also other retroviruses including MLV and MPMV require 
PI(4,5)P2 for efficient virus particle production [4, 10, 11]. However, not all retroviruses 
require PI(4,5)P2.  For example, although EIAV Gag that localizes both to the PM and 
intracellular compartments can bind PI(4,5)P2 [12], this Gag seems to depend on 
PI(3,5)P2 rather than PI(4,5)P2 for efficient virus release and membrane binding [5]. 
Similarly, HTLV-1, which also localizes at the PM and intracellular compartments, is 
less sensitive to PI(4,5)P2 depletion and is able to bind membranes efficiently even in the 
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absence of PI(4,5)P2 [13]. Thus, different classes of retroviruses may have evolved with 
different requirements in terms of targeting to the site of assembly and virus particle 
production.  
RNA bound to MA HBR inhibits PI(4,5)P2-independent membrane binding of Gag 
Summary of data 
In addition to binding acidic lipids, several in vitro studies have shown that the 
MA HBR can bind RNA [14-20]. In Chapter III, we have shown that RNase treatment of 
in vitro synthesized Gag significantly increases its binding to control liposomes that lack 
PI(4,5)P2 but still contain another acidic lipid, phosphatidylserine (PS). These data 
suggest that RNA inhibits membrane binding of Gag, especially in the absence of 
PI(4,5)P2. In addition to increasing the binding of Gag to liposomes containing acidic 
lipids, RNase treatment of Gag also had a modest increase in its binding to liposomes 
containing only a neutral lipid, PC, in a myristate–dependent manner. Thus, RNA likely 
acts as a negative regulator of non-specific membrane binding by blocking both 
electrostatic interactions of Gag with acidic lipids and to a lesser extent hydrophobic 
interactions determined by myristate exposure. Based on these data, we hypothesize that 
RNA binding to MA necessitates the involvement of PI(4,5)P2 for efficient membrane 
binding of Gag and is discussed later.  
Does RNA-mediated inhibition of Gag membrane binding occur in cells? 
  To shift to a cell-based study on the role of MA-bound RNA in membrane 
binding, the question that needs to be addressed first is whether MA HBR interacts with 
RNA in cells. To examine this question, we quantified the amount of RNA bound to cell-
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derived Gag mutants after immunoprecipitation. As expected, when NC, the major RNA-
binding domain in Gag was removed, there was significantly less RNA co-
immunoprecipitated with Gag compared to full-length Gag. The amount of RNA bound 
to Gag was also reduced when MA HBR was mutated, demonstrating that MA HBR 
binds RNA in cells (Fig. 4.3). To address whether the RNA bound to Gag in cells inhibits 
membrane binding, cytosolic Gag was isolated from digitonin-permeabilized HeLa cells 
transfected with HIV-1 molecular clones. The isolated Gag was then tested for its ability 
to bind liposomes with or without RNase treatment. As observed in chapter III using in 
vitro synthesized Gag, RNase treatment significantly enhanced binding of Gag to 
liposomes lacking PI(4,5)P2 (Fig.4.4). This suggests that RNA bound to Gag in cells can 
block non-specific membrane binding of Gag. We are currently investigating whether this 
RNA-mediated inhibition occurs in intact cells using microinjection and protein 
transfection methods. 
What is the identity of the RNA that inhibits membrane binding of Gag? 
The RNA molecules that are present in the in vitro studies performed using rabbit 
reticulocyte lysates are Gag mRNA, tRNA and rRNA. Based on these data, we performed 
an in vitro functional-rescue experiment by adding back different RNA species to RNase-
treated Gag. If there is any RNA specificity involved in the inhibition of membrane 
binding, specific RNA species are expected to inhibit membrane binding of Gag. 
However, preliminary studies suggest that any RNA, including Gag mRNA, tRNA or 
HeLa total RNA (that contains around 80% rRNA) is capable of inhibiting membrane 
binding of Gag (Fig.4.5). Assuming that a typical HeLa cell volume is 4x10
-6 μl and that 
a cell has around 10-30 pg of RNA, there is about 2.5-7.5μg/μl of RNA in a HeLa cell. 
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Under normal physiological conditions, eighty percent of cellular RNA is rRNA, 15-20 
% are tRNA or other small RNAs and the rest being mRNA. The concentration of RNA 
used in the functional-rescue assay is only around 0.11μg/μl, which is less than the 
physiological concentration. However, it is not known how much RNA is free (unbound 
RNA) in cells. It is conceivable that the RNA species bound to the MA HBR are 
restricted in cells, due to the limited amount of RNA that Gag encounters. In addition, it 
is possible that the same RNA that is bound to NC also binds MA. If this is the case, due 
to its inherent high affinity for RNA, NC may bring the RNA in close proximity to the 
MA HBR, which may then allow efficient MA-RNA interaction in cells. Further studies 
are required to address these possibilities. Overall, the results are consistent with the 
observation that several abundant RNA molecules interact non-specifically with Gag and 
are packaged into the virion [21].  
What would be the implication of MA-RNA interaction in the viral life cycle? 
  The MA-viral RNA interaction has been shown to be important for genomic RNA 
dimerization, encapsidation, or nucleocytoplasmic transport of Gag in other retroviruses 
[22-25].  However, there are no reports indicating similar roles for MA-RNA interaction 
in the HIV-1 life cycle. Nevertheless, there are several recent studies functionally linking 
nuclear export of HIV-1 gRNA and MA-mediated membrane binding. It is known that 
HIV-1 assembly is blocked in murine cells [26-29]. However, altering the RNA export 
pathway, or introducing mutations in MA, which enhance Gag membrane binding [30-
33], are sufficient to alleviate the block in HIV-1 assembly in murine cells [34]. Similar 
MA-dependent inhibition of assembly was also observed in human cells, when the native 
Rev response element (RRE) was replaced with Hepatitis B virus post-transcriptional 
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regulatory element (PRE) [35]. Thus, the membrane binding of Gag mediated by MA is 
functionally linked to the RNA export pathway used by HIV-1.   
As mentioned in the introduction, Rev is important for nuclear export of unspliced 
RNA that is packaged into the virus as genomic RNA. Interestingly, a recent study has 
shown that excessive amount of spliced RNA in the cytosol reduces virus release and 
replication of HIV, likely by inhibiting membrane binding and assembly of Gag [36]. In 
addition, a viral RNA packaging signal ( ) mutant that packages more spliced RNA 
compared to viral genomic RNA had a second site mutation in MA [37]. This mutation, 
which is a change from an acidic residue to a basic residue, rescued the replication of  
mutant by reverting to normal levels of spliced to unspliced RNA ratio in the virion. 
Interestingly, the second site mutant specifically excluded spliced RNA incorporation 
into the virion but did not alter the amount of unspliced RNA. Based on these data, we 
can speculate that in normal circumstances unspliced viral RNA may interact with NC 
and due to close proximity may also bind to MA. However, in the absence of such 
interaction as observed in packaging signal mutant, MA may have higher affinity for 
spliced RNA. To avoid such excessive amount of spliced viral RNA incorporation, the 
second site mutation in MA that has an additional basic residue may alter the structure of 
MA such that MA has enhanced affinity for acidic lipids like PI(4,5)P2 . Higher affinity 
for PI(4,5)P2 may then displace spliced RNA from MA, thus bringing back the spliced to 
unspliced RNA ratios in the virion to normal levels. On this note, it is interesting that 
another single amino acid mutation in MA that enhances PI(4,5)P2 specificity can rescue 
the block in assembly seen in murine cells [34]. The nature of the link between RNA 
export, splicing and membrane binding needs to be elucidated.   
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MA-PI(4,5)P2 binding may be important for coordinating Gag membrane binding 
with other assembly and post-assembly events 
As mentioned earlier, both myristate and HBR are necessary for efficient 
membrane binding of Gag. Either one alone is not sufficient in the context of full-length 
Gag in cells, as supported by observations that both non-myristoylated Gag and Gag 
derivatives with substitutions of all basic residues in the HBR do not bind membranes 
efficiently [38-42]. However, in contrast to amino acid substitutions in the HBR, deletion 
of the entire MA globular head except for the myristoylation signal enhances Gag 
membrane binding [33, 43-46].  Treating non-myristoylated Gag with RNase also rescues 
binding of this otherwise defective Gag to membranes that contain PS, an abundant acidic 
phospholipid in the inner leaflet of cell membranes [42].  These observations suggest that 
membrane binding is inhibited by the globular-head-dependent sequestration of myristate 
and potentially by RNA bound to the HBR. In this context, it is intriguing that PI(4,5)P2 
appears to be capable of reversing both modes of inhibition. Unlike PS, PI(4,5)P2 is able 
to bind MA HBR even in the presence of RNA [42, 47], perhaps because it binds to a site 
in MA not blocked by RNA or has a higher affinity for MA than the RNA. NMR studies 
on MA-PI(4,5)P2 interaction suggest that binding of Gag to PI(4,5)P2 causes a structural 
change that can expose myristate [3]. Thus, both targeting of Gag to PI(4,5)P2-enriched 
membranes, i.e. PM, and efficient membrane binding are tightly linked.  
NMR data further suggest that once the myristoyl moiety is exposed, the 
hydrophobic pocket of Gag is then occupied by the 2’ acyl chain of PI(4,5)P2 that is 
usually unsaturated [3]. This would leave two saturated acyl chains that mediate MA-
membrane interaction; the remaining saturated 1’ acyl chain of PI(4,5)P2, and the N-
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terminal myristoyl moiety of Gag (Fig. 4.6). The intriguing implication of this association 
is that it could enhance the affinity of Gag for PM microdomains known as lipid rafts, 
where saturated but not unsaturated acyl chains are preferred.  Consistent with this 
model, replacing N-terminal myristate with an unsaturated analog significantly reduces 
Gag in detergent-resistant membrane fractions that are thought to originate from lipid 
rafts [48].  Lipid rafts have been previously shown to play a crucial role in virus assembly 
and infectivity of progeny virus particles [48-52] (for review see [53, 54]).  Therefore, 
interaction with PI(4,5)P2 not only promotes specific Gag localization to the PM and 
stable membrane binding, but may also confer an additional advantage to HIV-1 by 
associating assembly events to lipid rafts. The latter role for PI(4,5)P2 has not been tested 
experimentally. 
As mentioned earlier, in vitro studies indicate that RNA bound to MA HBR can 
block interactions with PS but not with PI(4,5)P2 [42, 47].  Therefore, it is possible that 
the requirement for PI(4,5)P2 could be a mere consequence of RNA-mediated inhibition 
of MA interaction with other acidic lipids.  Conversely, RNA may be recruited to ensure 
specificity of the MA HBR for PI(4,5)P2 and membranes containing this lipid (i.e., the 
PM). Indeed, HTLV-1 Gag membrane binding that is less dependent on PI(4,5)P2 is also 
not inhibited by RNA, suggesting a correlation between RNA binding and PI(4,5)P2-
dependent membrane interaction[13]. Interestingly, a neutron scattering study showed 
that in solution, monomeric Gag adapts a conformation in which Gag is folded over, and 
MA and NC are in a close proximity [55]. When bound to either acidic membrane or 
oligonucleotides, Gag is still in a compact shape. However, when both acidic membrane 
and oligonucleotides are present, Gag forms the extended rod-like structure similar to the 
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structure observed in immature virion [56] (Fig. 4.6). An intriguing model proposed in 
these studies is that when bound to either the PM or RNA, Gag can do so via both basic 
regions in MA and NC simultaneously. When both the PM and RNA are present, 
however, MA-PM and NC-RNA interactions may occur in parallel. Thus, it is 
conceivable that once RNA-bound Gag reaches the PM, a high affinity of the MA HBR 
to PI(4,5)P2 may help strip RNA from MA, but not NC (Fig. 4.6). Consistent with this 
possibility, in vitro RNA chaperone activity (annealing of tRNA to the primer-binding 
site of viral RNA) of NC in the context of Gag increased several fold when IP6 was 
added to Gag or when MA was deleted [57]. These data suggest that RNA binding of MA 
hinders NC activities in the absence of inositol phosphates. Based on the above data, we 
speculate that RNA-mediated regulation of membrane binding may be a way of 
coordinating several major assembly steps for HIV-1. Once the MA HBR is bound to 
PI(4,5)P2 and releases RNA, NC may become capable of freely performing its functions, 
such as tRNA annealing and RNA-mediated Gag multimerization. However, it is 
important to note that this model assumes that the same RNA binds both MA and NC, an 
assumption that has to be tested experimentally.  
Interestingly, NC-mediated multimerization has been shown to be important for 
localization of Gag to the rear-end protrusions known as uropods in polarized T cells 
[58]. Therefore, binding of PI(4,5)P2 to MA might represent the transition from the MA-
driven PM-targeting phase to the NC-dependent uropod localization phase. Notably, 
these Gag-containing uropods form frequent contacts with other T cells and participate in 
virological synapses [58, 59] at which cell-to-cell virus transmission is thought to take 
place efficiently[60-63](for review see [64-68]). Therefore, this polarized localization of 
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Gag on the PM likely facilitates efficient cell-to-cell transfer of the virus at the contact 
sites, which might represent another advantage associated with targeting of Gag to the 
PM. Further studies are required to better understand the connection between the MA-
mediated regulation of targeting and membrane binding of Gag and the NC- mediated 
Gag multimerization step that drive Gag to specific sites within the plane of the PM. 
Conclusions 
Binding of Gag to the PM is the essential early step in HIV-1 assembly. These 
processes are likely modulated by MA in three different but coordinated ways: positively 
by interacting with PI(4,5)P2, negatively by suppressing myristate-mediated hydrophobic 
interaction, and negatively by interacting with RNA. With the present knowledge on 
Gag-membrane binding, several types of drugs can be developed for inhibiting this 
process during HIV-1 assembly. Blocking N-terminal myristoylation of Gag or 
supplementing cells with unsaturated analogues of myristate have already been shown to 
significantly reduce infectious virus particle production [48, 69-72]. Similarly, as the 
Gag- PI(4,5)P2 interaction plays an essential role in virus assembly, small molecule 
inhibitors that interfere with this interaction can be developed. Lately, RNA aptamers 
have been emerging as a new class of therapeutics for several different diseases [73]. 
With the recent evidence for the role of RNA in the inhibition of membrane binding of 
Gag, RNA aptamers that bind MA with higher affinity than PI(4,5)P2 might prove useful 
as inhibitors of HIV assembly (for example, see reference [20]). 
Mechanisms regulating both MA-PI(4,5)P2 and MA-RNA interactions, as well as 
their potential roles in coordinating Gag membrane binding and other steps in assembly 
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and post-assembly processes remain to be elucidated.  In addition, several events that 
precede Gag-membrane binding continue to pose outstanding questions: Where is Gag 
synthesized? How does Gag traffic to the PM at which PI(4,5)P2 stabilizes its membrane 
binding? When and where does Gag encounter the RNA that inhibits MA-dependent 
membrane binding? How and why are RNA-export pathway and membrane binding 
linked? Addressing these questions will provide new strategies to inhibit HIV-1 












Fig.4.1 PI(4,5)P2 is important for efficient virus release and membrane binding in 
macrophages 
Primary monocyte-derived macrophages were infected with VSV-G pseudotyped HIV 
containing 5ptaseIV(FL) or 5ptaseIV 1( 1) in the place of Nef. A) 36 hours post-
infection, virus-release assay was performed as in Fig. 2.8. Note that the virus release 
efficiency is reduced around 4 fold in 5ptaseIV expressing cells. B) Gag tagged with 
venus fluorescent protein was used for infection and 48 hours post-infection, the cells 
were fixed, permeabilized and stained with -Myc antibody to visualize 5ptaseIV 
expression. Note that in 5ptaseIV 1-expressing cells, GagVenus shows strong VCC 
localization but in 5ptaseIVFL-expressing cells, Gag shows hazy cytosolic signal with 







Fig.4.2. PI(4,5)P2 is important for efficient virus release of HIV-1 subtype C. 
HeLa cells were transfected with pMJ4 (HIV-1 subtype C) or pNL4-3 (HIV-1 subtype B) 
along with either pUC19(-) or 5ptaseIV(FL) or  5patseIV 1( 1). 16 hours post-
transfection, virus release assay was performed as in Fig. 2.8. The virus release efficiency 
is reduced 3 fold for MJ4 and 7 fold for NL4-3 in 5ptaseIV expressing cells compared to 





Fig.4.3. MA HBR interacts with RNA in cells  
HeLa cells were transfected with pNL4-3/1GA/PR-, pNL4-3/1GA/6A2T/PR- or pNL4-
3/1GA/delNC/PR- and radiolabeled overnight. Cells were lysed and immunoprecipitated 
with anti-HIV Ig antibody. The RNA bound to the immunoprecipitated samples was 
isolated using Qiagen miRNA isolation kit. The amount of RNA was quantified by 
fluorometry using ribogreen reagent. Simultaneously, the immunoprecipitated samples 
were analyzed on SDS-PAGE and the amount of Gag was quantified using 
phosphorscreen analysis. The amount of RNA was normalized to the Gag levels and the 
RNA bound to pNL4-3/1GA/PR- was set to 100%. Average of 3 different experiments is 
shown.  
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Fig.4.4. RNA inhibits membrane binding of cell-derived Gag 
HeLa cells were transfected with pNL4-3/1GA/PR-.16 hours post-transfection, cells were 
treated with digitonin and centrifuged at high-speed. The supernatant containing 
cytoplasmic Gag was treated with 10 μg of RNase A or left untreated and incubated at 
37° C for 20 minutes. Liposomes were then added and the reaction was further incubated 
for 15 minutes before performing sucrose gradient centrifugation. Five 0.8 ml fractions 
were collected and 50 μl of each fraction were loaded on gel and analyzed by western 
blotting using anti-HIV Ig primary antibody and anti-human Alexa Fluor488 secondary 
antibody. M: membrane bound, NM: non-membrane bound. 
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Fig. 4.5 Different RNA species can inhibit membrane binding of Gag 
Radiolabeled Gag synthesized using rabbit reticulocyte lysates was treated with 400 ng of 
RNase A at 37°C for 20 minutes. RNase A was blocked using 10 μl of RNasin (40 U/μl) 
and 5 μg of different RNA or buffer (-) was added (final concentration of RNA is 0.11 
μg/μl), and incubated at 30°C for 30 minutes. Liposomes were then added and incubated 
further for 15 minutes before performing sucrose gradient centrifugation. Five 1 ml 





Figure 4.6 Regulation of Gag-PM binding via MA-PI(4,5)P2 interaction and its 
possible impacts on subsequent assembly events 
Both sequestration of the N-terminal myristoyl moiety and binding of RNA to the HBR 
inhibit non-specific membrane binding of matrix (MA) via hydrophobic and electrostatic 
interactions, respectively. Once Gag reaches the plasma membrane, PI(4,5)P2 binds to the 
MA HBR thereby serving as a membrane anchor for Gag even when RNA is bound to the 
HBR. In addition, PI(4,5)P2 binding to MA exposes myristate, further enhancing 
membrane binding. Altogether, these positive and negative regulation mechanisms ensure 
the plasma membrane specificity of Gag.  Upon PI(4,5)P2 binding, sequestration of 2’ 
acyl chain of PI(4,5)P2 into a hydrophobic pocket vacated by the myristoyl moiety may 
result in Gag association with membrane via two saturated acyl chains. This is likely to 
increase propensity of Gag to partition into lipid rafts.  In addition, MA-PI(4,5)P2 
interaction might induce dissociation of RNA from MA, which in turn may facilitate NC-
mediated functions, such as higher-order multimerization. Therefore, it is possible that 
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